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Background-—Persistent congestion with deteriorating renal function is an important cause of adverse outcomes in heart failure.
We aimed to characterize new approaches to evaluate renal congestion using Doppler ultrasonography.
Methods and Results-—We enrolled 205 patients with suspected or prediagnosed pulmonary hypertension (PH) undergoing right
heart catheterization. Patients underwent renal Doppler ultrasonography and assessment of invasive cardiopulmonary hemody-
namics, echocardiography, renal function, intra-abdominal pressure, and neurohormones and hydration status. Four spectral
Doppler intrarenal venous ﬂow patterns and a novel renal venous stasis index (RVSI) were deﬁned. We evaluated PH-related
morbidity using the Cox proportional hazards model for the composite end point of PH progression (hospitalization for worsening PH,
lung transplantation, or PH-speciﬁc therapy escalation) and all-cause mortality for 1-year after discharge. The prognostic utility of
RVSI and intrarenal venous ﬂow patterns was compared using receiver operating characteristic curves. RVSI increased in a graded
fashion across increasing severity of intrarenal venous ﬂow patterns (P<0.0001) and was signiﬁcantly associated with right heart and
renal function, intra-abdominal pressure, and neurohormonal and hydration status. During follow-up, the morbidity/mortality end
point occurred in 91 patients and was independently predicted by RVSI (RVSI in the third tertile versus referent: hazard ratio: 4.72
[95% CI, 2.10–10.59; P<0.0001]). Receiver operating characteristic curves suggested superiority of RVSI to individual intrarenal
venous ﬂow patterns in predicting outcome (areas under the curve: 0.789 and 0.761, respectively; P=0.038).
Conclusions-—We propose RVSI as a conceptually new and integrative Doppler index of renal congestion. RVSI provides additional
prognostic information to stratify PH for the propensity to develop right heart failure.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT03039959. ( J Am Heart Assoc. 2019;8:
e013584. DOI: 10.1161/JAHA.119.013584.)
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H eart failure (HF) is a major cause of death worldwide
1
and the leading cause of hospitalization in both the
United States and Europe.2 In addition to low cardiac output,
persistent congestion with deterioration of renal function due
to progressive right ventricular (RV) failure has been identiﬁed
as an important cause of adverse outcomes in HF.3–5
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Congestion may lead to a vicious circle of renal dysfunc-
tion, increases in intra-abdominal pressure, neurohormonal
activation, excessive renal tubular sodium reabsorption, ﬂuid
overload, and diuretic resistance, leading to further RV
stress.6,7 Elevation of right atrial pressure (RAP) is transmitted
to the renal veins, causing increased interstitial and tubular
hydrostatic pressure within the encapsulated kidney, which
decreases net glomerular ﬁltration rate (GFR) and oxygen
delivery.8 Similar pathophysiological mechanisms are
expected to occur during increases in intra-abdominal pres-
sure.6 Congestion may also directly compress vessels in the
renal parenchymal regions or reduce vessel compliance.9
Consequently, changes in vessel shape and function may lead
to transient and cardiac cycle-dependent stasis of renal
venous ﬂow and to changes in intrarenal venous ﬂow (IRVF)
patterns.
Doppler ultrasonography was recently proposed to evalu-
ate renal congestion, with different IRVF patterns and the
intrarenal venous impedance index having been shown to
predict diuretic response and adverse outcomes in patients
with HF or undergoing cardiac surgery.9–12 However, these
approaches do not reﬂect the continuum of renal congestion:
classiﬁcation of IRVF patterns into different categories may
miss important changes within those categories, and the
venous impedance index does not distinguish between IRVF
patterns with different degrees of venous stasis. We sought to
identify and rigorously characterize a new approach to
evaluate the continuum of renal congestion based on Doppler
renal venous ﬂow.
Methods
Study Design and Participants
We prospectively enrolled consecutive hospital inpatients
aged ≥18 years with suspected or prediagnosed pulmonary
hypertension (PH) who were undergoing invasive right heart
catheterization (RHC) between January 2017 and September
2017 at the Department of Pulmonology, University Hospital
Giessen and Marburg, Giessen, Germany. PH is the most
common precursor to RV failure13 and thus represents an
ideal scenario for studying congestion. Suspicion of PH was
determined on clinical grounds including echocardiographic
evaluation, in accordance with the most recent guidelines for
the diagnosis and treatment of PH.14 Patients with prediag-
nosed PH had received the diagnosis based on previous RHC.
Diagnosis and classiﬁcation of PH and pulmonary vasoactive
treatment were based on current guidelines.14 PH was
deﬁned as invasively measured mean pulmonary arterial
pressure (PAP) ≥25 mm Hg at rest. Patients were assigned a
diagnosis of pulmonary arterial hypertension (group 1), PH
due to left heart disease (group 2), PH due to lung diseases
and/or hypoxia (group 3), chronic thromboembolic PH (group
4), or PH with unclear and/or multifactorial mechanisms
(group 5)14 by a multidisciplinary board. Patients receiving PH
therapy could enter the study without restrictions. HF was
diagnosed according to current guidelines.15
Patients were excluded if they had chronic kidney disease
stage 5, preexisting acute kidney injury, non–end-stage renal
disease with extracorporeal or peritoneal ultraﬁltration due to
diuretic-resistant ﬂuid overload, prediagnosed glomeru-
lonephritis, autosomal dominant polycystic kidney disease,
or postrenal obstruction; if they were recipients of solid-organ
transplants; or if they had received NSAIDs within 72 hours
before RHC. The exclusion criteria acute kidney injury and
chronic kidney disease were diagnosed by an adjudication
committee of 3 expert nephrologists. Chronic kidney disease
was considered as estimated GFR (eGFR; creatinine–cystatin
C equation) <60 mL/min per 1.73 m2 or the presence of
microalbuminuria independent of eGFR.16 Acute kidney injury
was deﬁned as an increase in serum creatinine by ≥0.3 mg/
dL within 48 hours or ≥1.5 times baseline within the prior 7
days17 (determined by all available serum creatinine values
from hospital and outpatient medical records within the
previous 90 days). Diuretic-resistant ﬂuid overload was
deﬁned as the inability to achieve an adequate negative ﬂuid
Clinical Perspective
What Is New?
• Doppler-derived intrarenal venous ﬂow patterns having been
shown to predict adverse outcomes in patients with heart
failure; however, these approaches do not reﬂect the
continuum of renal congestion because classiﬁcation of
intrarenal venous ﬂow into different categories may miss
important changes within those categories.
• In patients with suspected pulmonary hypertension under-
going right heart catheterization, we developed a continuous
index from intrarenal venous ﬂow patterns, and we propose
the renal venous stasis index as a conceptually new and
integrative Doppler measure of renal congestion.
• Our study suggests that renal venous stasis index may be
superior to individual intrarenal venous ﬂow pattern in
predicting outcome in patients with pulmonary hyperten-
sion.
What Are the Clinical Implications?
• Renal venous stasis index provides additional prognostic
information to stratify pulmonary hypertension for the
propensity to develop right heart failure.
• Longitudinal studies are needed to clarify the role of renal
venous stasis index in the management of pulmonary
hypertension.
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balance when the following 4 therapeutic options had been
exploited: (1) restriction of ﬂuid intake to <1.5 L/day and
sodium chloride intake to ≤6.0 g/day; (2) (continuous)
intravenous infusion of furosemide (minimum 500 mg/day);
(3) sequential nephron blockade with the addition of a thiazide
diuretic (eg, hydrochlorothiazide minimum 25 mg/day or
xipamide minimum 20 mg/day); (4) addition of an aldos-
terone antagonist if tolerable with serum potassium level
(spironolactone minimum 25 mg/day or eplerenone minimum
50 mg/day). RHC data, echocardiography, renal function,
IRVF patterns, laboratory measurements, intra-abdominal
pressure, and bioimpedance data were evaluated separately,
as described in the next section, by examiners who were
blinded to the other data. All patients were included in the
Giessen PH registry.18
The study was approved by the local Human Research
Ethics Committee (AZ 237/16) and complied with the
Declaration of Helsinki. The study was registered at Clini-
calTrials.gov (identiﬁer: NCT03039959). All participants gave
signed informed consent. The data that support the ﬁndings
of this study are available from the corresponding author on
reasonable request.
Procedures and Measurements
Renal Doppler ultrasonography
Ultrasound and spectral Doppler analyses were performed in
duplicate by 2 independent nephrologists with experience in
Doppler ultrasound, using an EPIQ 5 system (Philips Health-
care) with a sector transducer frequency range of 2.5–
5.0 MHz. The analyses were performed after a Swan-Ganz
catheter had been inserted for RHC assessment (described in
the next section) and the patient had rested in a supine
position for ≥10 minutes. Color Doppler images were used to
identify interlobar vessels. Pulsed Doppler waveforms of the
interlobar arteries and veins were recorded simultaneously
with the patient in a resting decubitus position. Except for
renal resistive index (RRI), which was assessed in both
kidneys, all renal Doppler ultrasonography studies were
performed in the right kidney (except in cases of unsatisfac-
tory image quality) because left renal vein phasicity may be
attenuated because of entrapment in the fork between the
abdominal aorta and the superior mesenteric artery. In
addition, the left ovarian or testicular veins drain into the
left renal vein, which, in the rare event of ovarian or testicular
varicosis, may affect renal venous ﬂow.
All values were recorded as means of at least 3 measure-
ments obtained in different interlobar vessels over 3 cardiac
cycles during sinus rhythm. If atrial ﬁbrillation was present, an
index beat (the beat following 2 preceding cardiac cycles of
equal duration) was used for each measurement. Venous
impedance index and RRI were calculated as follows:
(maximum ﬂow velocityminimum diastolic ﬂow velocity)/
maximum ﬂow velocity.9 A side-to-side difference in RRI of
>5% between the kidneys was considered indicative for
signiﬁcant renal artery stenosis.19 RRI <0.7 was regarded as
normal.20
IRVF patterns were characterized by a blinded adjudication
committee comprising a nephrologist, an angiologist, and a
pulmonologist blinded to clinical, laboratory, and RHC data. If
2 reviewers disagreed, a third reviewer provided input and
consensus was developed. The IRVF patterns were broadly
categorized into continuous (noncongestive) and discontinu-
ous (nadir velocity=0) ﬂow patterns. We further classiﬁed the
discontinuous IRVF patterns into 3 stages: pulsatile, biphasic
(with venous peaks during systole and diastole), and
monophasic (with venous peak during diastole; Figure 1).
To reﬂect the full continuum of renal congestion, we
deﬁned and evaluated a new, continuous ratio, the renal
venous stasis index (RVSI). RVSI indicates the proportion of
the cardiac cycle during which there is no renal venous outlet
ﬂow and is calculated as follows: (cardiac cycle timevenous
ﬂow time)/cardiac cycle time (Figure 2).
Right heart catheterization
On the day of RHC, each patient took his or her usual dose of
medication at 07:00 AM except for the maintenance dose of
diuretics. In patients with long-term oxygen treatment, oxygen
was applied via nasal cannula at the previously prescribed
ﬂow rate. A Swan-Ganz catheter (7F balloon tipped; Baxter
Healthcare) was inserted under local anesthesia in the right
internal jugular vein. RHC was performed according to current
guidelines,14 with assessment of mean PAP, RAP, pulmonary
vascular resistance, pulmonary capillary wedge pressure,
cardiac output (thermodilution method), cardiac index, mean
arterial pressure, and mixed venous oxygen saturation
immediately after renal ultrasonography (for details see
Data S1).
Echocardiography
Echocardiography was performed by experienced echocardio-
graphers 1 day before RHC using Vivid E9 and Vivid S5
systems (GE Healthcare). Right heart parameters (RV myocar-
dial performance index [Tei index], tricuspid annular plane
systolic excursion, systolic PAP, right atrial size, basal
diameter of the right ventricle, inferior vena cava diameter,
and systolic free wall myocardial velocity) and left heart
parameters (left atrial and ventricular diameters and the ratio
of mitral inﬂow velocity to lateral annular relaxation velocity
[E/e’]) were measured as recommended.21
Other measures
Body composition (including hydration status) was analyzed
by bioimpedance spectroscopy using the body composition
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monitor (Fresenius Medical Care; see Data S1) before
catheterization. Hydration status was also evaluated by
clinical assessment (edema) and ultrasound (ascites and
pleural effusion). Intra-abdominal pressure was measured via
an indwelling urinary catheter in all patients using the
transvesical method as previously described (Data S1).6 The
mean arterial pressure was calculated as follows: [systolic
blood pressure+(29diastolic blood pressure)]/3. The abdom-
inal perfusion pressure was determined as mean arterial
pressure minus intra-abdominal pressure.6 The renal ﬁltration
gradient can be estimated as glomerular ﬁltration pressure
minus proximal tubular pressure.6 In the presence of elevated
intra-abdominal pressure, proximal tubular pressure may be
assumed to equal intra-abdominal pressure, and thus
glomerular ﬁltration pressure can be estimated mean arterial
pressure minus intra-abdominal pressure. The renal ﬁltration
gradient was therefore calculated as follows: mean arterial
pressure(29intra-abdominal pressure). Intra-abdominal
pressures from 4 to 7 mm Hg were considered as normal
range, whereas values ≥12 mm Hg were considered as intra-
abdominal hypertension.22 Six-minute walk distance and New
York Heart Association functional class were assessed 1 day
before RHC according to current guidelines.15,23 Loop diuretic
doses were converted to furosemide equivalents with 20 mg
torasemide equal to 80 mg furosemide for oral diuretics and
20 mg torasemide equal to 40 mg furosemide for intravenous
diuretics.24 Thiazide diuretics included hydrochlorothiazide
and xipamide. If triamterene was taken, it was used in a ﬁxed
diuretic combination with hydrochlorothiazide. Aldosterone
antagonists included spironolactone and eplerenone.
Laboratory methods
Laboratory methods are detailed in Data S1. Brieﬂy, blood
samples were collected on the day of RHC from the Swan-
Ganz catheter after the patient had rested in a supine position
for ≥60 minutes. Urine samples were collected from ﬁrst
morning-void specimens. BNP (B-type natriuretic peptide),
copeptin, creatinine, and cystatin C were measured using
chemiluminescence, time-resolved ampliﬁed cryptate emis-
sion, photometric-enzymatic, and immunoturbidimetric
<1 1 1 1
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Figure 1. Congestion stages as deﬁned by intrarenal venous ﬂow patterns. Pulsed-wave Doppler samples of renal congestion patterns in the
interlobar renal vessel. The upward Doppler signal shows the intrarenal arterial ﬂow, which is used to measure renal resistive index; the
downward Doppler signal shows the venous ﬂow, used to measure venous impedance index or renal venous stasis index. A, No congestion:
continuous venous ﬂow. B, Stage 1 congestion: pulsatile venous ﬂow. C, Stage 2 congestion: biphasic venous ﬂow. D, Stage 3 congestion:
monophasic venous ﬂow. D indicates diastole; S, systole; VII, venous impedance index.
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methods, respectively. We chose BNP and copeptin as
biomarkers of neurohormonal activation because both are
commonly used for diagnosis and determining prognosis in
HF.15 The eGFR was determined using both creatinine25 and
creatinine–cystatin C26 Chronic Kidney Disease–Epidemiology
Collaboration equations.
Follow-Up and End Points
Clinical outcomes were evaluated for 1 year after discharge.
Patients were closely followed during the observation period
by clinical visits or telephone interviews. Changes of medi-
cation for clinical reasons were permitted (the primary
physician caring for the patient was blinded to the IRVF
patterns and RVSI results). Use of diuretics was at the
discretion of the treating physician. At 1 year, all patients
were recontacted for follow-up analyses at the nephrology
outpatient department. If the primary cause of PH was
surgically treated (eg, pulmonary thrombendarterectomy in
patients with chronic thromboembolic PH or lung transplan-
tation), the patients were followed until the surgical proce-
dure. If a patient died outside of the hospital, telephone calls
to the general practitioner or the family members were
performed to conﬁrm the date of death.
We evaluated the ﬁrst occurrence of a composite end point
of PH-related morbidity (any hospitalization for worsening of
PH, lung transplantation, or need for escalation of PH-speciﬁc
therapy) and death from any cause. In addition, the following
components of the composite end point were each analyzed
separately: unscheduled hospitalization due to ﬂuid overload
with requirement for an increase in diuretic therapy (eg, due
to pulmonary or peripheral edema, pleural effusion, ascites, or
recent increase of body weight by ≥10%); need for escalation
or change of PH-speciﬁc therapy due to clinical and echocar-
diographic progress of PH; and death from any cause. Patients
who underwent pulmonary thromboendarterectomy were
considered as withdrawn alive. All available medical records
were collected, and morbidity and mortality data were
evaluated according to the predeﬁned end point components
in a blinded fashion by a clinical end point adjudication
committee including medical experts in nephrology, PH, and
cardiology who were unaware of the IRVF patterns and RVSI
results and not responsible for the primary care of the patient.
Index cardiac cycle (ms) – venous flow (ms)
Renal venous stasis index =
Index cardiac cycle (ms)
Pulsatile Biphasic Monophasic
30
20
10
–10
–20
–30
Artery
flow
cm/s
Vein
flow
Cardiac cycle time Cardiac cycle time Cardiac cycle time
Venous flow time Venous flow time Venous flow time
Figure 2. Renal venous stasis index (RVSI). The RVSI is a novel Doppler-based parameter to estimate severity of renal congestion. Pulsed-
wave Doppler samples of renal congestion patterns in the interlobar renal vessel are shown. The upward Doppler signal shows the intrarenal
arterial ﬂow, which is used to measure cardiac cycle time; the downward Doppler signal shows the venous ﬂow, used to measure venous ﬂow
time. Under physiological conditions, the index is zero due to the presence of a continuous venous ﬂow, whereas it increases with rising severity
of congestion. The ﬁgure illustrates the method of measurement of RVSI in different congestion stages. ms indicates milliseconds.
 270 patients undergoing right 
heart catheterization were screened
 205 patients were included
in the analysis
65 patients were excluded
• 25 had pre-existing acute kidney injury  
• 6 had stage 5 chronic kidney disease  
• 1 had non-end-stage renal disease with
 extracorporeal ultrafiltration
• 3 had non-end-stage renal disease with
 peritoneal ultrafiltration
• 10 received non-steroidal inflammatory 
 drugs within 72 h before catheterization  
• 15 declined to participate
• 5 other reasons
Figure 3. Study ﬂow chart. The diagram describes the protocol
used for the enrollment of patients in this study.
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Table 1. Clinical Characteristics, Invasive Hemodynamics, Echocardiographic Data, Renal Function, and Neurohormonal and
Hydration Status According to RVSI Tertile
All patients(N=205) RVSI 0(n=59)
RVSI Tertiles
P Value*
First, 0 to ≤0.12
(n=49)
Second, >0.12 to
≤0.32 (n=48)
Third,
>0.32(n=49)
Demographics
Age, y 68.0 (57.0–78.0) 68.0 (55.0–73.0) 67.0 (51.0–75.5) 72.5 (61.0–78.0) 74.0 (65.0–81.0) 0.0152
Male, n (%) 87 (42.4) 24 (40.7) 17 (34.7) 17 (35.4) 29 (59.2) 0.0488
Body mass index, kg/m2 27.826.07 29.036.05 26.056.37 28.306.84 27.674.52 0.075
Baseline clinical data
Oxygen supply, n (%) 118 (57.6) 28 (47.5) 28 (57.1) 32 (66.7) 30 (61.2) 0.224
PaO2
† 69.3211.71 71.0910.74 68.1111.21 68.0010.01 69.6714.57 0.474
PaCO2
† 38.578.98 40.2011.68 37.767.30 37.387.88 38.597.66 0.367
6MWD, m 277.23136.05 309.76118.16 285.08156.43 283.77131.30 223.80127.02 0.0098
NYHA classification, n (%)
1–2 44 (21.5) 15 (25.4) 12 (24.5) 13 (27.1) 4 (8.2) 0.178
3–4 161 (78.5) 44 (74.6) 37 (75.5) 35 (72.9) 45 (91.8)
Laboratory data
Leukocytes, 9109/L 7.432.49 7.332.53 7.722.29 7.142.68 7.562.47 0.674
Hemoglobin, g/dL 13.272.09 13.951.83 13.532.06 13.492.18 13.022.31 0.504
Sodium, mmol/L 139.563.07 139.323.15 139.732.72 140.153.14 139.103.22 0.343
Potassium, mmol/L 3.670.42 3.650.40 3.640.34 3.630.44 3.730.47 0.612
Uric acid, mg/dL 6.772.52 6.262.18 5.892.07 6.652.31 8.382.82 <0.0001
Albumin, g/dL 38.203.22 38.913.18 37.493.25 38.092.96 38.182.42 0.162
C-reactive protein, mg/L 5.22 (1.52–11.44) 3.13 (1.07–8.60) 3.70 (0.50–11.58) 5.22 (2.05–11.48) 7.20 (3.18–14.51) 0.0172
Comorbidities, n (%)
Hypertension 128 (62.4) 35 (59.3) 29 (59.2) 32 (66.7) 32 (65.3) 0.800
Diabetes mellitus 48 (23.4) 12 (20.3) 9 (18.4) 9 (18.8) 18 (36.7) 0.092
Atrial fibrillation 56 (27.3) 7 (11.9) 14 (28.6) 9 (18.8) 26 (53.1) <0.0001
Maintenance therapy
ACEI or ARB, n (%) 83 (40.5) 23 (39.0) 18 (36.7) 20 (41.7) 22 (44.9) 0.858
b-Blocker 103 (50.2) 25 (42.4) 18 (36.7) 27 (56.3) 33 (67.3) 0.0095
Loop diuretic dose, mg/d‡ 40 (0.0–60.0) 20 (0.0–40.0) 20 (0.0–55.0) 30 (0.0–55.0) 80 (40.0–170.0) <0.0001
PH-specific therapy (%)
Treatment-naive 116 (56.6) 42 (71.2) 21 (42.9) 25 (47.9) 30 (61.2) 0.0292
Monotherapy 49 (23.9) 8 (13.6) 18 (36.7) 11 (22.9) 12 (24.5)
Dual therapy 28 (13.7) 6 (10.2) 7 (14.3) 12 (25.0) 3 (6.1)
Triple therapy 12 (5.9) 3 (5.1) 3 (6.1) 2 (4.2) 4 (8.2)
Hemodynamics
Mean PAP, mm Hg 34.8414.63 24.109.62 34.7812.79 41.1016.03 41.6912.39 <0.0001
PVR, dyne∙s/cm5 394 (214–604) 229 (110–420) 422 (214–589) 516 (279–679) 495 (313–833) <0.0001
RAP, mm Hg 5.765.63 2.463.66 3.883.76 5.563.72 11.806.06 <0.0001
Cardiac index, L/min/m2 2.730.98 2.981.01 2.881.16 2.670.68 2.320.89 0.0032
PCWP, mm Hg 9.0 (5.0–13.0) 7.0 (4.0–10.0) 8.0 (5.0–12.0) 9.5 (6.0–14.8) 12.0 (8.0–18.0) <0.0001
Continued
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Table 1. Continued
All patients(N=205) RVSI 0(n=59)
RVSI Tertiles
P Value*
First, 0 to ≤0.12
(n=49)
Second, >0.12 to
≤0.32 (n=48)
Third,
>0.32(n=49)
Mixed venous oxygen
saturation, %
63.768.35 66.706.42 65.157.17 65.005.85 57.6210.43 <0.0001
Heart rate, beats/min 71.6213.23 72.0011.32 69.8412.90 71.3811.49 73.1816.95 0.65
MAP, mm Hg§ 84.2511.57 85.2210.28 82.7613.39 84.8110.82 84.0211.99 0.72
Echocardiographic parameters
Right heart
TAPSE, mm 19.894.41 21.883.82 21.144.44 19.503.64 16.633.85 <0.0001
RV myocardial performance
index (Tei index)
0.490.22 0.460.20 0.450.21 0.540.24 0.490.24 0.334
RV S’, cm/s 11.603.52 12.953.31 12.133.27 11.493.29 9.543.36 <0.0001
TAPSE/systolic PAP ratio 0.390.21 0.550.24 0.380.22 0.330.12 0.300.12 <0.0001
Tricuspid insufficiency,
n (%)
<0.0001
Mild 66 (32.2) 34 (57.6) 10 (20.4) 12 (25.0) 10 (20.4)
Moderate 112 (54.6) 23 (39.0) 31 (63.3) 32 (66.7) 26 (53.1)
Severe 25 (12.2) 1 (1.7) 7 (14.3) 4 (8.3) 13 (26.5)
RA area, cm2 18.896.72 15.146.30 18.485.64 19.215.64 23.586.44 <0.0001
RV diameter, mm 40.788.08 37.937.38 41.096.97 40.527.75 44.409.00 0.0005
IVC, cm 2.270.49 2.010.52 2.260.42 2.340.41 2.530.43 <0.0001
Left heart
LVEF, % 60.0 (60.0–65.0) 60 (60.0–65.0) 62 (60.0–65.0) 60 (60.0–65.0) 60 (55.0–65.0) 0.0442
LA diameter, mm 41.986.86 39.786.35 40.336.98 41.426.16 46.435.98 <0.0001
LVEDD, mm 46.035.59 46.284.73 45.265.73 45.836.23 46.675.81 0.65
E/e’ ratio 12.985.34 11.073.52 12.464.50 14.095.69 14.796.78 0.0023
Renal function
Serum creatinine, mg/dL|| 1.010.45 0.920.40 0.790.21 0.980.36 1.350.55 <0.0001
Cystatin C, mg/L 1.10 (0.91–1.52) 0.98 (0.81–1.24) 1.01 (0.88–1.18) 1.27 (0.97–1.62) 1.53 (1.10–2.09) <0.0001
Urea, mg/dL¶ 47.4435.85 40.9726.71 34.2913.13 44.6925.25 71.1054.75 <0.0001
eGFR (CKD-EPI creatinine
equation),
mL/min/1.73 m2#
74.4526.12 80.0724.52 87.3118.86 72.6924.01 56.5726.75 <0.0001
eGFR (CKD-EPI creatinine–
cystatin C equation),
mL/min/1.73 m2**
68.5826.86 77.6827.65 80.8020.25 64.0622.56 49.8424.49 <0.0001
Renal filtration
gradient, mm Hg††
69.3012.46 73.7010.60 69.6213.32 69.8111.12 63.2012.81 <0.0001
Urine PCR, mg/g creatinine 58.8 (40.2–114.2) 51.5 (36.4–72.6) 55.3 (37.5–85.4) 58.0 (39.9–92.9) 116.2 (49.1–190.8) <0.0001
Urine ACR, mg/g creatinine 11.4 (6.3–29.7) 9.3 (5.2–16.0) 9.0 (5.7–18.5) 10.3 (6.7–19.0) 29.7 (11.7–107.8) <0.0001
Urine a1MCR, mg/g
creatinine
10.9 (6.0–19.1) 8.7 (5.1–16.5) 8.7 (5.7–15.1) 12.0 (6.5–21.4) 15.4 (7.6–32.7) 0.0092
Renal Doppler ultrasonography
Venous impedance index 0.840.26 0.440.12 1.000 1.000 1.000 <0.0001
RRI 0.710.07 0.690.08 0.690.07 0.730.07 0.740.06 <0.0001
Continued
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Statistical Analysis
Descriptive statistics were expressed as meanSD or median
(interquartile range [IQR]) for continuous variables, and
frequency (percentage) for categorical variables. Patient char-
acteristics were compared between subgroups using ANOVA,
Mann-Whitney U tests, or Kruskal–Wallis tests for continuous
variables and v2 tests for categorical variables. Intra- and
interobserver reliability was evaluated using the intraclass
correlation coefﬁcient. To understand the relationships of renal
function and RVSI with other continuous variables, we
performed Spearman and Pearson correlation analysis. Corre-
lation coefﬁcient values >0.3 were considered relevant.
Kaplan-Meier analysis was performed to determine the
relationship of RVSI and IRVF patterns with clinical end points.
Risk factors for clinical end points were determined with Cox
proportional hazards models. Univariate factors with P<0.05
were entered into the multiple Cox regression model. A
stepwise backward procedure was used in multiple Cox
regression analysis (likelihood ratio). RVSI values >0 were
divided into tertiles, and then the hazard rates of each tertile for
reaching the clinical end points were calculated in relation to
the control group (RVSI=0). Receiver operating characteristic
curves were used to evaluate RVSI and IRVF as predictors of
binary clinical end points. Time-to-event information and
censoring were ignored when computing the areas under the
curves. Receiver operating characteristics were compared with
the DeLong test implemented in the R package pROC
Table 1. Continued
All patients(N=205) RVSI 0(n=59)
RVSI Tertiles
P Value*
First, 0 to ≤0.12
(n=49)
Second, >0.12 to
≤0.32 (n=48)
Third,
>0.32(n=49)
Neurohormonal status
BNP, pg/mL 138.0 (50.0–321.0) 46.0 (26.0–113.0) 98.0 (38.0–264.5) 198.5 (111.3–322.5) 468.0 (228.5–820.0) <0.0001
Copeptin, pmol/L 11.1 (5.8–23.3) 9.1 (4.6–16.0) 7.3 (4.9–14.4) 14.0 (5.2–23.5) 23.2 (11.1–39.6) <0.0001
Urine feNa, % 0.6 (0.4–1.3) 0.7 (0.4–1.2) 0.6 (0.4–1.1) 0.6 (0.4–1.2) 1.2 (0.4–2.1) 0.072
Hydration status
Peripheral edema, n (%) 60 (29.3) 13 (22.0) 11 (22.4) 16 (33.3) 20 (40.8) 0.105
Pleural effusion, n (%) 17 (8.3) 3 (5.1) 3 (6.1) 3 (6.3) 8 (16.3) 0.137
Ascites, n (%) 7 (3.4) 0 (0) 1 (2.0) 0 (0) 6 (12.2) 0.0013
Hydration status (as
measured by
bioimpedance)‡‡
0.712.12 0.141.41 0.501.78 1.182.41 1.502.48 <0.0001
ECW/ICW ratio‡‡ 0.880.12 0.850.11 0.850.09 0.890.13 0.910.13 0.0286
Intra-abdominal pressure measurement
Intra-abdominal
pressure, mm Hg
7.0 (6.0–9.0) 6.0 (5.0–6.0) 6.0 (6.0–7.0) 7.0 (7.0–8.0) 10.0 (9.0–12.0) <0.0001
Abdominal perfusion
pressure, mm Hg§§
76.7811.81 79.4610.38 77.3110.89 76.1913.32 73.6112.21 0.078
Values are meanSD or median (interquartile range) except as noted. Additional data are provided in the Data S1. ACEI indicates angiotensin-converting enzyme inhibitor; ACR, albumin/
creatinine ratio; a1MCR, a1-microglobulin/creatinine ratio; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; ECW, extracellular water; E/e’ ratio, ratio of mitral inﬂow velocity to lateral annular relaxation velocity; eGFR, estimated glomerular ﬁltration rate; feNa, fractional excretion of
sodium; ICW, intracellular water; IVC, inferior vena cava; LA, left atrial; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure;
NYHA, New York Heart Association; PAP, pulmonary arterial pressure; PCR, protein/creatinine ratio; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR,
pulmonary vascular resistance; RA, right atrial; RAP, right atrial pressure; RRI, renal resistive index; RV, right ventricular; RV S’, systolic annular tissue velocity of the lateral tricuspid
annulus; RVSI, renal venous stasis index; 6MWD indicates 6-min walk distance; TAPSE, tricuspid annular plane systolic excursion.
*After application of the Bonferroni correction, P<0.0008 was considered signiﬁcant.
†Blood gas measurements were taken from arterialized capillary ear lobe blood during right heart catheterization. In patients with long-term oxygen treatment, oxygen was applied by nasal
cannula at the previously prescribed ﬂow rate. To convert mm Hg to kPa, multiply by 0.133.
‡A total of 14 patients received intravenous furosemide.
§MAP was calculated as follows: (systolic blood pressure+[29diastolic pressure])/3.
||To convert the values for serum creatinine to lmol/L, multiply by 88.4.
¶To convert the values for urea to blood urea nitrogen, multiply by 0.467.
#eGFR was calculated with the CKD-EPI equation based on serum creatinine.25
**eGFR was calculated with the CKD-EPI equation based on serum creatinine and cystatin C.26
††The renal ﬁltration gradient was calculated as follows: MAP–(29intra-abdominal pressure).6
‡‡Additional bioimpedance data are provided in Data S1.
§§Abdominal perfusion pressure was calculated as MAP minus intra-abdominal pressure.6
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(1.14.0).27,28 Overall, the signiﬁcance level was set at a=0.05
except in multiple Cox regression analysis, where the signif-
icance level was a=0.10. The Bonferroni correction was applied
to adjust for multiple testing. The size of the RHC cohort was
estimated based on feasibility considerations. The power to
detect a hazard ratio >2.0 at a=0.05 between the third tertile
RVSI group (n=49) versus RVSI=0 (n=59) was 50%. The power
was calculated in R (3.5.1) using the function powerCT from the
package powerSurvEpi (0.1.0), based on a method proposed by
Freedman.27,29,30 All other statistical analyses were performed
using SPSS 23.0 software (IBM Corp).
Results
Patients
Of 270 eligible patients undergoing RHC, 205 patients were
enrolled and included in the analysis (Figure 3). None were
lost to follow-up. In all patients except 2, renal Doppler
studies were performed in the right kidney. IRVF pattern
classiﬁcations were completely consistent, and RVSI mea-
surements showed excellent reliability in both intra- and
interobserver comparisons (Table S1). Patients’ baseline
characteristics are shown in Table 1 and Table S2.
Association of RVSI with IRVF patterns and
demographic and clinical characteristics
After completion of recruitment, we conﬁrmed the predeﬁned
IRVF patterns with invasive hemodynamics and echocardio-
graphy and assessed their associations with other parameters
(Figure S1 and Table S3). By deﬁnition, patients with no renal
congestion had RVSI=0 and were assigned as the referent
group. As shown, RVSI showed a signiﬁcant stepwise increase
along the predeﬁned IRVF patterns (P<0.0001; Figure 4).
Table 1 and Figure 5 show the associations of RVSI tertiles
with key clinical parameters (additional parameters are shown
in Table S4). Cardiopulmonary hemodynamics (evaluated by
RHC) worsened with increasing RVSI tertile, with RAP showing
the clearest association. RV systolic function (tricuspid
annular plane systolic excursion) showed a signiﬁcant step-
wise decrease along the tertiles, with manifest dysfunction at
the highest tertile. Right atrial and ventricular diameter, left
atrial diameter, and E/e’ ratio signiﬁcantly increased along
the RVSI tertiles.
Patients with no congestion had normal mean serum
creatinine and eGFR values. From the second RVSI tertile
onward, there was gradual lower eGFR and renal ﬁltration
gradient across RVSI tertiles, whereas from RVSI=0 (no
congestion) to the ﬁrst RVSI tertile, there was no signiﬁcant
change in serum creatinine (P=0.09), eGFR (P=0.53), and
cystatin C (P=0.70). RRI signiﬁcantly increased with increas-
ing RVSI tertile. Of note, none of the patients exhibited a
signiﬁcant difference in mean RRI values between kidneys
(indicative of renal artery stenosis). There was a signiﬁcant
increase in proteinuria, albuminuria, and tubular proteinuria
(a1-microglobulin) with increasing RVSI tertile, but the median
values stayed within the physiological range.
RVSI tertiles were associated with levels of BNP and
copeptin, as well as hydration status (as measured by
bioimpedance), loop diuretic dose, and intra-abdominal pres-
sure. Fluid overload was detected as an extracellular ﬂuid
expansion in relation to intracellular ﬂuid depletion. Of note,
all patients with ascites were in the highest RVSI tertile and
exhibited a monophasic IRVF pattern except 1 patient who
was diagnosed with hepatitis C–associated liver cirrhosis and
porto-PH who was within the ﬁrst RVSI tertile.
Correlation analyses (Figure S2 and Table S5) showed
relevant and statistically signiﬁcant relationships between
RVSI and cardiopulmonary hemodynamics, echocardiographic
parameters, renal function, intra-abdominal pressure, and
neurohormonal and hydration status. As expected, tricuspid
insufﬁciency had an impact on RVSI values (median RVSI: 0.00
[IQR: 0.15–0.36] in mild, 0.13 [IQR: 0.17–0.46] in moderate,
and 0.33 [IQR: 0.26–0.72] in severe tricuspid insufﬁciency;
P<0.0001). However, in multivariate Cox regression analysis,
RVSI was superior to tricuspid insufﬁciency in predicting the
composite end point and all individual components. Further-
more, RVSI values were signiﬁcantly increased in patients with
versus without atrial ﬁbrillation (0.28 versus 0.09; P<0.0001);
this large difference was not due to interobserver variability
(intraclass correlation coefﬁcient was >0.9 in both groups).
Of the echocardiographic and hemodynamic parameters
assessed, right atrial area and RAP showed the strongest
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Figure 4. Association of renal venous stasis index with con-
gestion stages. Under physiological conditions, the renal venous
stasis index is zero due to the presence of a continuous venous
ﬂow, whereas it increases with rising severity of congestion.
Horizontal lines indicate median, boxes indicate interquartile
range (IQR), and whiskers indicate minimum and maximum
values. Data labels show median (IQR).
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correlations with renal function (Table S6). Arterial blood gas
measurements showed no correlation with renal function.
Analysis of PH subtypes
Baseline parameters signiﬁcantly differed across the PH
subtype groups, and conﬁrmed the correctness of the
classiﬁcation of each group (Table S7). All 30 patients with
PH due to left heart disease had HF with preserved ejection
fraction (Table S2). Patients with PH due to left heart disease
exhibited the highest RVSI values and were most likely to
have a monophasic pattern; they also had the poorest right
and left heart function, lowest renal function, and highest BNP
levels and intra-abdominal pressures.
Clinical outcomes
All 205 patients were included in the analysis of outcomes.
During the observational period (12 months [range: 11–13
months]), the composite end point of PH-related morbidity
and death from any cause occurred in 91 of 205 patients
(Table S8). We observed 64 (31.2%) unscheduled hospitaliza-
tions for ﬂuid overload, 71 (34.6%) escalations of PH-speciﬁc
therapy, and 21 (10.2%) deaths. Five patients underwent
pulmonary thromboendarterectomy, and 1 patient underwent
lung transplantation.
Patients in higher RVSI tertiles had increased rates of the
composite end point (Figure 6) and 2 of the individual
components (Figure S3). Analysis of outcomes by IRVF
patterns showed broadly similar trends but with some
overlap between the groups with biphasic and monophasic
IRVF patterns (Figure S4). In multiple Cox regression
analysis, RVSI tertiles remained independent predictors of
the composite end point and 2 of the individual components
(Table 2; univariate analyses are provided in Tables S9–
S12).
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Figure 5. RVSI and associated clinical parameters. Severity of renal congestion can be evaluated by measurement of RVSI using renal Doppler
ultrasonography. The ﬁgure illustrates the associations of RVSI tertiles with RAP and renal function (A), right ventricular systolic function and RA area
(B), neurohormonal status (C), and hydration status (D). Fluid overload as measured by bioimpedance is likely to occur because of hemodynamic
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eGFR, estimated glomerular ﬁltration rate (based on Chronic Kidney Disease Epidemiology Collaboration creatinine–cystatin C equation); RA, right
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During the observational period, 3 patients developed stage
3 acute kidney injury with diuretic-resistant ﬂuid overload and
required RRT; all 3 exhibited a monophasic IRVF pattern with a
median RVSI of 0.64 (IQR: 0.59–0.73) at baseline.
RVSI versus IRVF patterns for prediction of clinical
outcomes
Receiver operating characteristic curves suggested that RVSI
was amore sensitive and speciﬁc predictor of the composite end
point than the individual IRVF patterns (areas under the curve:
0.789 and 0.761, respectively; P=0.038; Figure S5). The
maximal Youden statistic was obtained for an RVSI cutoff of
0.14, yielding 77% speciﬁcity and 63% sensitivity. RVSI ≥0.14
was also an independent predictor of the composite end point
when added in multiple Cox regression analysis instead of RVSI
tertiles. A model including both RVSI and IRVF patterns as
predictor variables indicated superiority of RVSI over IRVF
patterns (Wald values: 2.817 and 2.059, respectively). Compar-
isons of RVSI and IRVF patterns for prediction of the individual
component end points are shown in Figure S5 and Table S13.
Discussion
We developed a continuous index from Doppler-derived IRVF
patterns and propose the RVSI as a simple, noninvasive, and
integrative Doppler measure of renal congestion. In patients
undergoing RHC based on clinical grounds, the RVSI was
correlated with invasive hemodynamics. Furthermore, our
data suggest that the RVSI may be superior to individual IRVF
patterns in predicting outcome.
Elevated RAP has been identiﬁed as a main driver of
deteriorating renal function in acutely decompensated HF.3–5
Only 3 HF studies9–11 have previously investigated the
association of Doppler-derived IRVF patterns and venous
impedance index with RAP and their utility in predicting
diuretic response and adverse outcomes. Furthermore, we
assessed the tricuspid annular plane systolic excursion/
systolic PAP ratio as a parameter of right ventricle–pulmonary
artery coupling, which was recently demonstrated to be
associated with prognosis in patients with pulmonary arterial
hypertension and HF with preserved ejection fraction.31,32 The
association of the tricuspid annular plane systolic excursion/
systolic PAP ratio and RVSI further emphasizes the meaning
of RVSI as a marker of renal congestion, as it mirrors not only
RV failure but also right ventricle–pulmonary artery uncou-
pling when afterload exceeds contractility.
IRVF depends on extrinsic factors (interstitial pressure and
intra-abdominal pressure) and intravenous pressure, which is
highly dependent on RAP.33–35 Under physiological condi-
tions, intrarenal veins exhibit continuous ﬂow independent of
renal function,36,37 with superimposed biphasic forward
velocities that peak during systole (reﬂecting right atrial
ﬁlling during RV ejection) and diastole (reﬂecting RAP release
after the tricuspid valve opens and RV ﬁlling occurs). With
increasing RAP, intrarenal veins become less compliant,
dampening the continuous ﬂow to a discontinuous (RVSI>0)
ﬂow and increasing prominence of the superimposed biphasic
forward velocities. Further increases in RAP may ultimately
lead to a diastolic-only (monophasic) ﬂow pattern, in which
renal venous outﬂow may exclusively depend on RV ﬁlling. Of
note, the increase in RAP during end-diastole (corresponding
to atrial contraction) can be transmitted to the renal veins,
potentially causing a reversal of vein ﬂow, as recently
described38; this may have been masked by the arterial
waveforms in our analysis of interlobar arteries and veins.
Deterioration of renal function in right HF appears to be
mainly hemodynamic (congestive), independent of PH sub-
type, and associated with activation of the neurohormonal
system and ﬂuid overload. This type of congestive nephropa-
thy can be described as a gradual decrease of renal function
as RVSI worsens, with no proteinuria even at severe
congestion. Interestingly, we see no signiﬁcant changes in
creatinine, eGFR, or cystatin C in patients with RVSI in the
ﬁrst tertile compared with normal RVSI (=0). This could be
explained by renal lymphatic ﬂow increasing dramatically with
early congestion, consequently preventing an increase in renal
interstitial pressure until full saturation,39,40 and suggests that
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Table 2. Predictors of Clinical End Points Identiﬁed by the Cox Proportional Hazards Model
Predictor
Univariate Multiple
HR (95% CI) P Value HR (95% CI) P Value
PH-related morbidity and death from any cause
RVSI tertiles 20.57 (9.03–46.87) <0.0001 0.0015
First tertile group vs RVSI 0 2.31 (1.06–5.05) 0.0363 2.30 (0.95–5.53) 0.064
Second tertile group vs RVSI 0 3.63 (1.71–7.65) 0.0007 3.41 (1.49–7.81) 0.0037
Third tertile group vs RVSI 0 8.70 (4.33–17.48) <0.0001 4.72 (2.10–10.59) <0.0001
Congestion stages 2.00 (1.63–2.44) <0.0001 0.0012
Stage 1 vs stage 0 2.65 (1.29–5.44) 0.0078 2.61 (1.18–5.80) 0.0182
Stage 2 vs stage 0 6.35 (3.08–13.09) <0.0001 4.90 (2.15–11.18) <0.0001
Stage 3 vs stage 0 8.45 (3.98–17.96) <0.0001 4.07 (1.68–9.85) 0.0019
Uric acid 1.25 (1.16–1.34) <0.0001 1.15 (1.05–1.26) 0.0017
Atrial fibrillation 2.56 (1.68–3.88) <0.0001 1.94 (1.05–3.56) 0.0355
6MWD 0.997 (0.996–0.999) 0.0006 0.997 (0.995–0.999) 0.0099
LA diameter 1.07 (1.04–1.10) <0.0001 1.05 (1.01–1.10) 0.0301
Age 1.02 (1.00–1.03) 0.0439 0.98 (0.96–1.00) 0.079
Unscheduled hospitalization due to fluid overload
RVSI tertiles 1.71 (1.48–1.98) <0.0001 0.0016
First tertile group vs RVSI 0 6.49 (1.42–29.64) 0.0157 5.50 (1.09–27.85) 0.0395
Second tertile group vs RVSI 0 10.98 (2.52–47.76) 0.0014 6.27 (1.36–28.96) 0.0187
Third tertile group vs RVSI 0 35.60 (8.54–148.38) <0.0001 13.01 (2.95–57.34) 0.0007
Congestion stages 2.49 (1.94–3.20) <0.0001 0.0193
Stage 1 vs stage 0 7.36 (1.71–31.72) 0.0074 5.01 (1.14–22.07) 0.0334
Stage 2 vs stage 0 25.51 (6.05–107.67) <0.0001 8.84 (1.98–39.46) 0.0043
Stage 3 vs stage 0 32.17 (7.44–139.09) <0.0001 5.06 (1.02–25.20) 0.0478
Uric acid 1.29 (1.19–1.41) <0.0001 1.27 (1.13–1.43) <0.0001
PCWP 1.08 (1.05–1.11) <0.0001 1.04 (1.01–1.08) 0.0159
Urine a1MCR 1.01 (1.01–1.02) <0.0001 1.01 (1.00–1.02) 0.0262
Atrial fibrillation 4.05 (2.47–6.63) <0.0001 1.88 (1.00–3.54) 0.0510
6MWD 0.996 (0.994–0.998) <0.0001 0.99 (0.99–1.00) 0.0006
RA area 1.11 (1.07–1.14) <0.0001 1.05 (1.00–1.10) 0.0477
Urine feNa 1.21 (1.07–1.36) 0.0017 0.82 (0.67–1.00) 0.0547
NYHA classification 1.81 (1.24–2.64) 0.0022 0.60 (0.34–1.05) 0.074
Escalation of PH-specific therapy
Mixed venous oxygen saturation 0.92 (0.90–0.95) <0.0001 0.96 (0.93–1.00) 0.0403
Uric acid 1.26 (1.16–1.36) <0.0001 1.31 (1.02–1.26) 0.0242
RVSI tertiles 1.43 (1.26–1.63) <0.0001 0.0186
First tertile group vs RVSI 0 2.16 (0.89–5.24) 0.087 1.89 (0.68–5.27) 0.2241
Second tertile group vs RVSI 0 3.52 (1.53–8.07) 0.0030 2.91 (1.13–7.51) 0.0271
Third tertile group vs RVSI 0 7.03 (3.22–15.35) <0.0001 4.29 (1.63–11.27) 0.0031
Congestion stages 1.86 (1.49–2.33) <0.0001 0.0106
Stage 1 vs stage 0 2.37 (1.05–5.35) 0.0373 2.13 (0.84–5.37) 0.110
Continued
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an increase of RVSI from 0 to the ﬁrst tertile may be a more
sensitive marker to identify patients at risk for subsequent
renal function decline than established biomarkers such as
creatinine and cystatin C. Transmission of venous congestion
to the renal veins is thought to impair GFR by increasing
pressure in the efferent end of the glomerular capillary, which
reduces glomerular–capillary hydrostatic pressure8; this can
be reversed by lowering renal venous pressure in experimen-
tal models.34 As an additional component, concomitant
elevation of renal interstitial pressure is likely to reduce
glomerular net ultraﬁltration pressure by opposing glomeru-
lar–capillary hydrostatic pressure and to reduce renal blood
ﬂow, as shown by the signiﬁcant increases in RRI in our
population. Future studies need to determine whether ther-
apies that reduce RAP will improve renal function and
particularly which RAP range must be achieved to provide
an acceptable balance of RV and renal function.
Our study has all the limitations of retrospective analyses of
prospectively collected data. Limitations include its single-
center design, selection bias, and moderate sample size and
duration of follow-up. We assumed that the monophasic IRVF
pattern reﬂects venous pressure release resulting from RV
ﬁlling, but we did not determine end-diastolic ﬁlling pressures
or RV volumes. In addition, entering RVSI and congestion
stages to 1 Cox regression model was done for comparison of
their prognostic value but may lead to overﬁtting of the model.
All echocardiography data were collected 1 day before RHC.
Although PH-speciﬁc therapy was not initiated or changed in
the interval between these assessments, some patients
received additional diuretics when ﬂuid overload was present,
which limits the interpretation of echocardiography relative to
RHC data. Renal venous congestion does not necessarily
indicate right HF because tricuspid insufﬁciency with intact RV
function may also induce congestion, and discontinuous IRVF
patterns have been described in obstructive nephropathy,41
where they are at least partly explained by increased renal
interstitial pressure subsequent to ureter obstruction.
Our study conﬁrmed the prognostic relevance of renal
venous congestion, and the novel RVSI in particular showed
promise as a simple, noninvasive, and objective Doppler
measure. RVSI and IRVF patterns may be useful to identify
patients who are likely to experience adverse outcomes.
Longitudinal studies are needed to clarify their roles in the
management of HF.
Conclusions
Our analyses of patients undergoing RHC present RVSI as a
novel Doppler measurement of renal congestion that may be
superior to IRVF patterns in predicting outcome in patients
with PH. Further studies are needed to validate our ﬁndings
and assess the utility of RVSI in PH management.
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Data S1. 
 
SUPPLEMENTAL METHODS 
Study design and participants 
 
Data collection 
Clinical variables were abstracted from patient medical records. All clinical and laboratory data, including 
patient demographics, were collected and stored in a password-protected dataset.  
 
Right heart catheterization (RHC) 
All RHC measures were derived at end-expiration, and reported values represent the average of 5 to 10 cardiac 
cycles. Cardiac output (average of three cycles with <10% variation in patients in sinus rhythm and five cardiac 
cycles in patients with atrial fibrillation) was derived by both thermodilution and the Fick method using 
nomograms for oxygen uptake in conjunction with the Fick method. If patients did not have supplemental 
oxygen therapy, the direct Fick method was performed directly after oxygen uptake assessment. When a 
discrepancy was present between both methods, cardiac output was reported by direct Fick; if direct Fick 
measurement was not possible, thermodilution was used. Pulmonary vascular resistance and cardiac index were 
calculated as described previously (pulmonary vascular resistance=[mean pulmonary arterial 
pressure−pulmonary capillary wedge pressure]/cardiac output; cardiac index=[cardiac output/body surface 
area]).1  
 
Bioimpedance spectroscopy 
Bioimpedance is based on the principle that the body acts as a circuit with a given resistance (opposition of 
current flow through intracellular and extracellular solutions [Ri and Re]) and reactance (the capacitance of cells 
to store energy [Xc]).2 The volume of the body fluid component is largely reflected in the resistance, whereas 
reactance might represent cell membrane integrity. The impedance is composed of the sum of resistance and 
reactance (√[R2
 
+ Xc2]).3 Another parameter that can be derived is the phase angle, which is the arc tangent of 
Xc/R. When a current passes through cells, a portion of the electrical current is stored and subsequently released 
in a different phase, termed “phase angle”. The phase angle is related to the ability of cells to function as 
capacitors, which is dependent on the integrity of the cell membrane and cellular health. Bioimpedance data 
from the study population are provided in Table S4.  
The three-compartment model of the BCM Body Composition Monitor has been validated against standard 
reference methods for assessment of fluid status and body composition in patients undergoing hemodialysis and 
peritoneal dialysis, albeit partly against gold standard techniques in healthy controls only.4-7 BCM has been 
shown to be valid in different ethnicities5, and measures impedance at 50 different frequencies between 5 kHz 
and 1 MHz. Reproducibility of BCM-derived parameters is high, with a coefficient of variation for the inter-
observer variability for extracellular water and total body water around 1.2% in studies8 performed in patients 
undergoing hemodialysis. Therefore, only one BCM measurement was performed in each individual patient. 
BCM results are normalized by sex and patient height. According to the manufacturer’s recommendations we 
excluded patients if they had an unipolar pacemaker, while there were no limitations for patients with stents 
or bipolar pacemakers.9 For measurement, the skin was cleansed with alcohol, then the electrodes were attached 
to one hand and one foot at the ipsilateral side, after the patient had been supine for at least 5 minutes and not 
touching any metal objects. 
Hydration status (expressed in Liters) was derived from the impedance data based on a physiologic tissue model 
that separates the body into three compartments4: surplus water, normohydrated lean tissue, and fat tissue. 
Hydration status represents the difference between the measured amount of extracellular water and the amount 
of water expected in normohydrated tissue conditions. Patients are considered ‘dehydrated’ or ‘overhydrated’ 
when their absolute hydration status is below the 10th or above the 90th percentile of the normal, presumed 
healthy, reference population, respectively (corresponding to 1.1 L of negative or positive hydration status, 
respectively).10, 11 Due to bio-physical reasons, bioimpedance spectroscopy does not measure sequestered fluid in 
the trunk, and presence of pleural effusion and ascites was documented by ultrasound.12 Lean tissue mass 
represents the body mass without adipose tissue and excess extracellular water (fluid overload). Fat represents 
the mass of adipose lipids in the body. Lean tissue mass and fat are provided in kilograms as well as in relation 
to body weight (%). Lean tissue index is calculated as the quotient of lean tissue mass/height. Fat tissue index is 
defined as the quotient of adipose tissue mass/height. Adipose tissue mass is the mass of the adipose tissue, 
including the adipose water. Body cell mass represents the cellular, metabolically active body mass, excluding 
the extracellular fluid in the metabolically active tissue.12  
 
Intra-abdominal pressure measurement  
Intra-abdominal pressure was measured with a standard Foley catheter, which was connected to a pressure 
transducer placed in-line with the iliac crest at the midaxillary line. The Foley catheter was flushed with a 
maximal instillation volume of 50 mL sterile saline via the aspiration port of the Foley catheter with the drainage 
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tube clamped to allow a fluid-filled column to develop up into the bladder. A pressure transducer was then 
inserted in the aspiration port, and the pressure was measured. The intra-abdominal pressure was expressed in 
mm Hg and was measured at end-expiration in the supine position, ensuring that abdominal muscle contractions 
were absent.  
 
Laboratory methods 
Blood and urine samples were centrifuged for 10 minutes at 3000xg and 5 minutes at 500xg, respectively. 
Samples were processed within 30 minutes of collection.  
B-type natriuretic peptide (BNP) and parathormone were measured by the chemiluminescence method on an 
Advia Centaur XPT analyzer (Siemens Healthcare GmbH, Erlangen, Germany). BNP >35 pg/mL was taken as 
the cut-off for diagnosing chronic heart failure.13 Copeptin was measured by the Time-Resolve-Amplified 
Cryptate Emission method on a Brahms Kryptor Compact Plus (Thermo Fisher Scientific, MA, USA). The range 
of copeptin, a surrogate marker for proarginine vasopressin release and neurohormonal activation, in healthy 
individuals has been recently described as 4.2 [9.5] pmol/L.14 Serum aldosterone was measured by the 
radioimmunological method on a Multi Crystal LB 2111 Gamma Counter (Berthold Technologies, Bad 
Wildbach, Germany). Urine sodium-to-potassium ratio <2 was considered as a marker of hyperaldosteronism. 
Urine fractional excretion of sodium <1% was considered as a marker of sodium retention. Cystatin C was 
measured by the immunoturbidimetric method on an AU5800 Chemistry Analyzer (Beckman Coulter, 
California, USA) with reference material ERM-DA471/IFCC (distributed by the European Joint Research 
Institute for Reference Materials and Measurements, Geil, Belgium).15 Creatinine was measured by the 
photometric-enzymatic method on an Advia Centaur XPT analyzer, with calibration to isotope dilution mass 
spectrometry reference measurements. Blood urea nitrogen-to-creatinine ratio >20 was considered as a marker of 
neurohormonally mediated disproportionate reabsorption of urea compared with that of creatinine.16 Creatinine 
clearance was calculated as: urine creatinine (mg/dL) x urine volume (mL) x1.73 (m2)/1440 min x serum 
creatinine (mg/dL) x body surface area (m2). For calculation of urea clearance, creatinine was substituted with 
urea. 
Proteinuria was measured using a colorimetric method with pyrogallol red on an AU5800 Chemistry Analyzer. 
Albuminuria was measured by the immunoturbidimetric method on a Advia Centaur XPT, and alpha 1-
microglobulin was measured by the immunonephelometric method on a BNII analyzer (Siemens Healthcare 
GmbH, Erlangen, Germany). Protein-to creatinine ratio, albumin-to-creatinine ratio, and alpha 1-microglobulin-
to-creatinine ratio (all reported in units of mg/g creatinine) were then calculated. Microalbuminuria and 
increased tubular proteinuria (alpha 1 microglobulin) were defined as values >30mg/g and >20mg/g creatinine, 
respectively.17, 18 Positive acanthocyturia, a diagnostic criterion of glomerulonephritis, was defined as >5% 
acanthocytes in centrifuged urinary sediment detected with a phase-contrast microscope Eclipse Ci-L (Nikon, 
Tokyo, Japan).19 Sterile leukocyturia, associated with interstitial nephritis, nephrolithiasis, uroepithelial tumors, 
and infection with atypical organisms, was defined as a positive urinary dip stick test for leukocyte esterase in 
combination with a negative urine culture.20  
 
Renal replacement therapy (RRT) 
Patients with fluid overload received a stepped pharmacological diuretic therapy including adjustable doses of 
intravenous loop diuretic agents, thiazide diuretic agents, and aldosterone antagonists. Patients who fulfilled the 
criteria for diuretic resistance despite the stepped pharmacological therapy were transferred to RRT, as were 
patients who developed stage 3 acute kidney injury with fluid overload or a life-threatening complication (eg, 
pulmonary edema).21 Modality of RRT was based on illness acuteness, patient preference, and co-morbidities 
(eg, presence of ascites). In general, peritoneal dialysis (conventional surgical technique; peritoneal dialysis 
catheter type Oreopoulous-Zellermann) was the preferred modality for patients with HF, except patients with 
life-threatening indications or cardiovascular instability, for whom slow extended daily hemodialysis with the 
GENIUS dialysis system (Fresenius Medical Care, Bad Homburg, Germany) was preferred.  
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Table S1. ICC for RVSI measured by two independent nephrologists. 
 
 
Intraclass 
correlation* 
95% confidence interval F test with true value 0 
Lower bound Upper bound Value df1 df2 Significance 
Inter-observer reliability 
Single measures 0.978† 0.973 0.982 178.709 204 612 0.000 
Average measures 0.994‡ 0.993 0.996 178.709 204 612 0.000 
Intra-observer reliability 
TS – single measures 1.000† 1.000 1.000  204   
TS – average measures 1.000‡ 1.000 1.000  204   
FH-S – single measures 1.000† 1.000 1.000 5302.258 204 204 0.000 
FH-S – average measures 1.000‡ 1.000 1.000 5302.258 204 204 0.000 
Two-way mixed effects model where people effects are random and measures effects are fixed. 
 
*Type A ICCs using an absolute agreement definition for inter-observer reliability; Type C ICCs using a 
consistency definition for intra-observer reliability. 
†The estimator is the same, whether the interaction effect is present or not. 
‡This estimate is computed assuming the interaction effect is absent, because it is not estimable otherwise. 
df=degrees of freedom; ICC=intraclass correlation coefficient; RVSI=renal venous stasis index. 
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Table S2. Classification of the RHC Cohort According to PH Subcategories. 
 
 n (%) 
No PH 40 (100) 
   Disease control 27 (67.5) 
   HF with preserved ejection fraction 13 (32.5) 
Group 1 (PAH) 46 (100) 
   Idiopathic PAH 27 (58.7) 
   Connective tissue disease 8 (17.4) 
   Congenital systemic-to-pulmonary shunts 6 (13.0) 
   Porto-pulmonary PH 5 (10.9) 
Group 2 (PH due to left heart disease) 30 (100) 
   PH-HF with preserved ejection fraction 30 (100) 
Group 3 (PH due to lung disease and/or hypoxemia) 41 (100) 
   Chronic obstructive pulmonary disease 22 (53.7) 
   Interstitial lung disease 15 (36.6) 
   Sleep-disordered breathing 4 (9.8) 
Group 4 (chronic thromboembolic PH) 34 (100) 
Group 5 (PH with unclear multifactorial mechanisms) 14 (100) 
   Sarcoidosis 9 (64.3) 
   Churg-Strauss syndrome 1 (1.6) 
   Unknown mechanisms 4 (28.6) 
 
HF denotes heart failure, PAH pulmonary arterial hypertension, PH pulmonary hypertension, and RHC right 
heart catheterization
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 Table S3. Clinical characteristics, invasive hemodynamics, echocardiographic data, renal function, and neurohormonal and hydration status stratified according to 
congestion stages as determined by intrarenal venous flow patterns. 
 All patients 
(n=205) 
No congestion  
(n=59) 
Stage 1 congestion  
(n=77) 
Stage 2 congestion  
(n=44) 
Stage 3 congestion  
(n=25) 
p value* 
 
Baseline clinical data       
6MWD, m 277.23±136.05  309.76±118.16  296.83±142.97 224.55±127.15 232.80±137.57 0.0022 
NYHA classification, n (%)       0.078 
   1–2 44 (21.5) 15 (25.4) 22 (28.6) 4 (9.1) 3 (12)  
   3–4 161 (78.5) 44 (74.6) 45 (71.4) 40 (90.9) 22 (88)  
Oxygen supply, n (%) 118 (57.6) 28 (47.5) 45 (58.4) 33 (75.0) 12 (48.0) 0.0306 
Maintenance therapy       
ACEi or ARB, n (%) 83 (40.5) 23 (39.0) 33 (42.9) 13 (29.5) 14 (56.0) 0.178 
Loop diuretic dose, mg/day     40.0 [0.0–60.0] 20.0 [0.0–40.0] 20.0 [0.0–45.0] 40.0 [0.0–80.0] 80.0 [40.0–200.0] <0.0001 
Thiazide diuretic, n (%)  72 (35.1) 18 (30.5) 27 (35.1) 17 (38.6) 10 (40.0) 0.789 
Aldosterone antagonist, n (%) 76 (37.1) 16 (27.1) 30 (39.0) 17 (38.6) 13 (52.0) 0.168 
Triamterene, n (%) 5 (2.4) 0 (0) 3 (3.9) 2 (4.5) 0 (0) 0.307 
PH-specific therapy, n (%)      0.433 
Treatment-naïve 116 (56.6) 42 (71.2) 36 (46.8) 24 (54.5) 14 (56.0)  
Monotherapy 49 (23.9) 8 (13.6) 23 (29.9) 11 (25.0) 7 (28.0)  
Dual therapy 28 (13.7) 6 (10.2) 13 (16.9) 6 (13.6) 3 (12.0)  
Triple therapy 12 (5.9) 3 (5.1) 5 (6.5) 3 (6.8) 1 (4.0)  
Hemodynamics       
Mean PAP, mm Hg 34.84±14.63 24.10±9.62 37.14±15.02 42.84±12.33 39.00±13.11 <0.0001 
PVR, dyn.s/cm5 394 [214–604] 229 [110–420] 440 [277–600] 558 [293–829] 428 [245–750] <0.0001 
RAP, mm Hg 5.76±5.63 2.46±3.66 4.44±4.75 9.00±5.04 11.88±7.54 <0.0001 
Cardiac index, L/min/m2 2.73±0.98 2.98±1.01 2.76±1.00 2.47±0.70 2.48±1.13 0.0332 
PCWP, mm Hg 9.0 [5.0–13.0] 7.0 [4.0–10.0] 9.0 [6.0–13.0] 10.5 [6.0–15.8] 12.0 [8.5–18.5] <0.0001 
Mixed venous oxygen saturation, % 63.76±8.35 66.70±6.42 65.11±6.59 59.83±9.70 59.60±10.63 <0.0001 
Heart rate, beats/min 71.62±13.23 72.00±11.32 70.34±12.55 72.23±13.49 73.60±18.51 0.703 
MAP, mm Hg† 84.25±11.57 85.22±10.28 83.71±12.18 85.69±13.06 81.09±9.48 0.375 
Echocardiographic parameters       
Right heart       
TAPSE, mm 19.89±4.41 21.88±3.82 20.87±4.01 18.18±3.80 15.20±3.46 <0.0001 
RV myocardial performance index (Tei 
index) 
0.49±0.22 0.46±0.20 0.47±0.23 0.55±0.23 0.48±0.22 0.323 
RV S’, cm/s 11.60±3.52 12.95±3.31  12.18±3.20 10.17±3.23 9.08±3.43 <0.0001 
TAPSE/Systolic PAP ratio 0.39±0.21 0.56±0.27 0.35±0.15 0.30±0.11 0.30±0.13 <0.0001 
Tricuspid insufficiency, n (%)      0.0007 
   Mild 66 (32.2) 34 (57.6) 15 (19.5) 12 (27.3) 5 (20)  
   Moderate 112 (54.6) 23 (39.0) 51 (66.2) 25 (56.8) 13 (52)  
   Severe  25 (12.2) 1 (1.7) 10 (13.0) 7 (15.9) 7 (28)  
RA area, cm2 18.89±6.72 14.14±6.30 18.87±5.70 20.99±6.24 24.16±6.60 <0.0001 
RV diameter, mm 40.78±8.08 37.93±7.38 40.43±6.68 43.40±8.86 44.04±9.86 0.0009 
IVC, cm 2.27±0.49 2.01±0.52 2.30±0.44 2.45±0.31 2.51±0.54 <0.0001 
Left heart       
LVEF, % 60.0 [60.0–65.0] 60 [60.0–65.0] 60 [60.0–65.0] 60 [55.0–65.0] 60 [52.5–60.5] 0.0552 
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 LA diameter, mm 41.98±6.86 39.78±6.35 40.65±6.51 43.17±6.12 48.56±5.85 <0.0001 
LVEDD, mm 46.03±5.59 46.28±4.73 45.10±5.45 46.24±7.01 47.84±4.85 0.184 
E/e’ ratio 12.98±5.34 11.07±3.52 12.96±4.12 13.80±6.52 16.42±8.07 0.0007 
Renal function       
Serum creatinine, mg/dL‡ 1.01±0.45 0.92±0.40 0.86±0.26 1.13±0.53 1.44±0.52 <0.0001 
Cystatin C, mg/L 1.10 [0.91–1.52] 0.98 [0.81–1.24] 1.06 [0.88–1.29] 1.33 [1.03–1.64] 1.83 [1.34–2.22] <0.0001 
Urea, mg/dL§ 47.44±35.85 40.97±26.71 37.12±17.31 59.84±56.61 72.72±32.68 <0.0001 
eGFR (CKD-EPI creatinine equation), 
mL/min/1.73 m2|| 
74.45±26.12 80.07±24.51 81.57±21.49 67.25±27.96 51.96±24.92 <0.0001 
eGFR (CKD-EPI creatinine-cystatin C 
equation), mL/min/1.73 m2# 
68.58±26.86 77.68±27.65 74.42±21.81 59.42±25.85 45.24±23.37 <0.0001 
Renal filtration gradient, mm Hg** 69.30±12.46 73.70±10.60 70.36±12.08 67.64±13.00 58.61±10.42 <0.0001 
Urine PCR, mg/g creatinine 58.8 [40.2–114.2] 51.5 [36.4–72.6] 55.3 [38.4–93.3] 70.3 [46.9–160.5] 116.2 [52.7–222.7] 0.0022 
Urine ACR, mg/g creatinine 11.4 [6.3–29.7] 9.3 [5.2–16.0] 10.3 [6.2–22.2] 13.8 [8.1–45.8] 33.4 [11.3–223.7] <0.0001 
Urine α1MCR, mg/g creatinine 10.9 [6.0–19.1] 8.7 [5.1–16.5] 10.4 [5.9–19.0] 11.7 [7.0–25.3] 16.3 [8.3–40.1] 0.0283 
Acanthocyturia, n (%) 7 (3.4) 2 (3.4) 3 (3.9) 2 (4.5) 0 (0) 0.775 
Sterile leukocyturia, n (%) 2 (1.0) 1 (1.7) 0 (0) 1 (2.3) 0 (0) 0.555 
Renal Doppler ultrasonography       
RVSI 0.11 [0.00–0.32] 0 [0.0–0.0] 0.10 [0.07–0.14] 0.33 [0.20–0.41] 0.56 [0.48–0.74] <0.0001 
Venous impedance index  0.84±0.26 0.44±0.12 1.00±0 1.00±0 1.00±0 <0.0001 
RRI 0.71±0.07 0.69±0.08 0.70±0.07 0.74±0.06 0.75±0.06 <0.0001 
Neurohormonal status       
BNP, pg/mL 138.0 [50.0–321.0] 46.0 [26.0–113.0] 150.0 [50.5–254.5] 303.0 [147.0–633.8] 534.0 [228.5–776.5] <0.0001 
Copeptin, pmol/L 11.1 [5.8–23.3] 9.1 [4.6–16.0] 7.9 [5.2–15.4] 18.8 [7.3–29.8] 27.7 [13.7–50.7] <0.0001 
Sodium, mmol/L 139.56±3.07 139.32±3.15 139.57±2.80 140.59±2.86 138.24±3.60 0.0206 
Urine FeNa, % 0.6 [0.4–1.3] 0.7 [0.4–1.2] 0.6 [0.4–1.1] 0.5 [0.4–1.5] 1.3 [0.5–2.5] 0.073 
BUN-to-creatinine ratio 21.15±7.53 20.48±7.14 20.16±6.52 20.35±9.39 23.63±7.22 0.131 
Aldosterone, ng/dL 5.60 [3.1–11.8] 4.90 [3.0–8.6] 4.90 [3.0–13.4] 6.15 [3.0–11.7] 10.50 [4.2–19.1] 0.0531 
Potassium, mmol/L 3.67±0.42 3.65±0.40 3.65±0.41 3.77±0.453 3.66±0.42 0.591 
Urine Na/K ratio 3.23±2.24 3.84±2.58 3.20±2.28 2.68±1.47 2.88±2.17 0.0532 
Hydration status       
Ascites, n (%) 7 (3.4) 0 (0) 1 (1.3) 0 (0) 6 (24.0) <0.0001 
Pleural effusion, n (%) 17 (8.3) 3 (5.1) 5 (6.5) 2 (4.5) 7 (28.0) 0.0021 
Peripheral edema, n (%) 60 (29.3) 12 (22.0) 22 (28.6) 15 (34.1) 10 (40.0) 0.335 
Hydration status (as measured by 
bioimpedance), L 
0.71±2.12 -0.14±1.41 0.78±2.24 1.16±2.09 1.70±2.55 0.0006 
Total body water, L  37.78±7.47 37.93±8.71 36.78±6.99 39.46±7.20 37.73±5.86 0.359 
ECW, L 17.55±3.30 17.36±3.79 16.94±3.01 18.50±3.38 18.31±2.32 0.069 
ICW, L 20.28±4.53 20.56±5.24 19.85±4.43 20.97±4.24 19.83±3.32 0.574 
ECW/ICW ratio 0.95±0.15 0.86±0.11 0.86±0.11 0.89±0.11 0.94±0.14 0.0204 
Intra-abdominal pressure measurement       
Intra-abdominal pressure, mm Hg 7.0 [6.0–9.0] 6.0 [5.0–6.0] 7.0 [6.0–7.0] 9.0 [8.0–10.0] 11.0 [10.0–13.0] <0.0001 
Abdominal perfusion pressure, mm Hg†† 76.78±11.81 79.46±10.38 77.04±12.09 76.67±12.96 69.85±9.67 0.0078 
Values are mean±SD, median [interquartile range], or n (%). 
D
ow
nloaded from
 http://ahajournals.org by on October 29, 2019
 *After application of the Bonferroni correction, p<0.0008 was considered significant. †MAP was calculated as (systolic blood pressure+2x diastolic pressure)/3. ‡To convert the 
values for serum creatinine to μmol/L, multiply by 88.4. §eGFR was calculated with the CKD-EPI equation based on serum creatinine.23 ||To convert the values for urea to BUN, 
multiply by 0.467. #eGFR was calculated with the CKD-EPI equation based on serum creatinine and cystatin C.22 **The renal filtration gradient was calculated as: MAP–2x 
intra-abdominal pressure.24 ††The abdominal perfusion pressure was calculated using the equation: MAP–intra-abdominal pressure.24 
6MWD=6-min walk distance; ACEi=angiotensin-converting enzyme inhibitor; ACR=albumin-to-creatinine ratio; α1MCR=α1-microglobulin-to-creatinine ratio; 
ARB=angiotensin receptor blocker; BUN=blood urea nitrogen; BNP=b-type natriuretic peptide; CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; 
ECW=extracellular water; E/e’ ratio=ratio of mitral inflow velocity to lateral annular relaxation velocity; eGFR=estimated glomerular filtration rate; FeNa=fractional excretion of 
sodium; ICW=intracellular water; IVC=inferior vena cava; LA=left atrial; LVEDD=left ventricular end-diastolic diameter; LVEF=left ventricular ejection fraction; MAP=mean 
arterial pressure; Na/K=sodium/potassium; NYHA=New York Heart Association; PAP=pulmonary arterial pressure; PCR= protein-to-creatinine ratio; PCWP=pulmonary 
capillary wedge pressure; PH=pulmonary hypertension; PVR=pulmonary vascular resistance; RA=right atrial; RAP=right atrial pressure; RRI=renal resistive index; RV=right 
ventricular; RV S’=systolic annular tissue velocity of the lateral tricuspid annulus; RVSI=renal venous stasis index; TAPSE=tricuspid annular plane systolic excursion. 
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 Table S4. Additional data on clinical characteristics, invasive hemodynamics, echocardiographic data, 
renal function, neurohormonal and hydration status according to congestion stages as determined by 
renal venous stasis index. 
   RVSI tertiles  
 All patients 
 
(n=205) 
RVSI=0 
 
(n=59) 
First 
0<RVSI≤0.12 
(n=49) 
Second 
>0.12<RVSI≤0.32 
(n=48) 
Third 
RVSI>0.32 
(n=49) 
p 
value* 
 
Maintenance therapy, 
n (%) 
      
Calcium channel 
blocker 
46 (22.4) 10 (16.9) 11 (22.4) 14 (29.2) 11 (22.4) 0.518 
Thiazide diuretic  72 (35.1) 18 (30.5) 18 (36.7) 17 (35.4) 19 (38.8) 0.826 
Aldosterone antagonist 76 (37.1) 16 (27.1) 24 (49.0) 12 (25.0) 24 (49.0) 0.0095 
Triamterene 5 (2.4) 0 (0) 2 (4.1) 3 (6.3) 0 (0) 0.103 
Renal function, n (%)       
Acanthocyturia 7 (3.4) 2 (3.4) 2 (4.1) 1 (2.1) 2 (4.1) 0.942 
Sterile leukocyturia 2 (1.0) 1 (1.7) 0 (0) 0 (0) 1 (2.0) 0.605 
Neurohormonal status       
BUN-to-creatinine ratio 21.15±7.53 20.48±7.14 20.38±6.60 20.78±6.93 23.06±9.14 0.236 
Aldosterone, ng/dL 5.60 [3.1–11.8] 4.9 [3.0–8.6] 5.9 [3.0–13.5] 4.7 [3.0–11.8] 7.2 [4.1–16.7] 0.0292 
Urine Na/K ratio 3.23±2.24 3.84±2.58 3.34±2.35 2.87±1.76 2.76±1.98 0.0470 
Hydration status, n 
(%) 
      
Total body water, L  37.78±7.47 37.93±8.71 36.50±7.30 37.82±6.19 38.92±7.11 0.495 
Extracellular water, L 17.55±3.30 17.36±3.79 16.62±2.95 17.80±3.17 18.54±2.87 0.0450 
Intracellular water, L 20.28±4.53 20.56±5.24 19.88±4.66 20.03±3.64 20.62±4.27 0.812 
Values are mean±SD, median [interquartile range], or n (%).  
*After application of the Bonferroni correction, p<0.004 was considered significant.  
BUN=blood urea nitrogen; Na/K=sodium/potassium; PH=pulmonary hypertension; RVSI=renal venous stasis 
index. 
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 Table S5. Correlation of RVSI with relevant parameters*. 
 RVSI 
Correlation coefficient 
p value† 
Demographics   
Age 0.238 0.0006 
Body mass index – 0.025 0.720 
Clinical variables   
6MWD – 0.239 0.0006 
Loop diuretic dose 0.369 <0.0001 
Hemodynamics   
Mean PAP 0.472 <0.0001 
PVR 0.321 <0.0001 
RAP 0.584 <0.0001 
Cardiac index – 0.321 <0.0001 
PCWP 0.404 <0.0001 
Mixed venous oxygen saturation – 0.391 <0.0001 
Echocardiographic parameters   
Right heart   
TAPSE – 0.456 <0.0001 
RV myocardial performance index (Tei index) 0.037 0.672 
RV S’ – 0.357 <0.0001 
TAPSE/Systolic PAP ratio – 0.332 <0.0001 
RA area 0.471 <0.0001 
RV diameter 0.272 <0.0001 
IVC 0.355 <0.0001 
Left heart   
LVEF – 0.163 0.0201 
LA diameter 0.404 <0.0001 
E/e’ ratio 0.250 0.0006 
Renal function   
Serum creatinine 0.394 <0.0001 
Urea 0.427 <0.0001 
Cystatin C 0.462 <0.0001 
eGFR (MDRD equation) ‡ – 0.365 <0.0001 
eGFR (CKD-EPI creatinine equation)§ – 0.365 <0.0001 
eGFR (CKD-EPI creatinine-cystatin C equation)|| – 0.433 <0.0001 
Renal filtration gradient# – 0.327 <0.0001 
Urine PCR 0.315 <0.0001 
Urine ACR 0.341 <0.0001 
Urine α1MCR 0.233 0.0008 
RRI 0.323 <0.0001 
Neurohormonal status   
BNP 0.623 <0.0001 
Copeptin 0.350 <0.0001 
Hydration status   
Hydration status (as measured by bioimpedance) 0.301 <0.0001 
ECW/ICW ratio 0.178 0.0141 
Intra-abdominal pressure measurement   
Intra-abdominal pressure 0.772 <0.0001 
Abdominal perfusion pressure** – 0.214 0.0021 
Pearson or Spearman correlation was considered as appropriate. *Relevant parameters were chosen based on 
their clinical role; in addition, parameters that showed a significant difference across RVSI tertiles (table 2) were 
included. †After application of the Bonferroni correction, p<0.0014 was considered significant. ‡eGFR was 
calculated with the MDRD equation based on serum creatinine.25 §eGFR was calculated with the CKD-EPI 
equation based on serum creatinine.23 ||eGFR was calculated with the CKD-EPI equation based on serum 
creatinine and cystatin C.22 #The renal filtration gradient was calculated as: MAP–2x intra-abdominal pressure.24 
**The abdominal perfusion pressure was calculated using the equation: MAP–intra-abdominal pressure.24 
6MWD=6-min walk distance; ACR=albumin-to-creatinine ratio; α1MCR=α1-microglobulin-to-creatinine ratio; 
CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; BNP=b-type natriuretic peptide; 
ECW=extracellular water; E/e’ ratio=ratio of mitral inflow velocity to lateral annular relaxation velocity; 
eGFR=estimated glomerular filtration rate; ICW=intracellular water; IVC=inferior vena cava; LA=left atrial; 
LVEF=left ventricular ejection fraction; MAP=mean arterial pressure; MDRD=Modification of Diet in Renal 
Disease; PAP=pulmonary arterial pressure; PCR=protein-to-creatinine ratio; PCWP=pulmonary capillary wedge 
pressure; PVR=pulmonary vascular resistance; RA=right atrial; RAP=right atrial pressure; RRI=renal resistive 
index; RV=right ventricular; RV S’=systolic annular tissue velocity of the lateral tricuspid annulus; RVSI=renal 
venous stasis index; TAPSE=tricuspid annular plane systolic excursion.   
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 Table S6. Correlation of renal function with relevant parameters*.  
 Serum creatinine 
 
Correlation 
coefficient 
p value† eGFR (CKD-EPI 
creatinine-cystatin C 
equation) 
Correlation coefficient 
p value† 
Demographics     
Age, yrs 0.342 <0.0001 –0.542 <0.0001 
Baseline clinical data     
PaO2‡ –0.021 0.764 0.028 0.685 
PaCO2‡ 0.005 0.944 0.053 0.451 
6MWD –0.211 0.0023 0.350 <0.0001 
Laboratory data     
Hemoglobin –0.166 0.0173 0.258 0.0002 
Uric acid 0.479 <0.0001 –0.510 <0.0001 
C-reactive protein 0.213 0.0022 –0.282 <0.0001 
Maintenance therapy     
Loop diuretic dose 0.482 <0.0001 –0.389 <0.0001 
Hemodynamics     
RAP 0.293 <0.0001 –0.323 <0.0001 
PCWP 0.265 <0.0001 –0.270 <0.0001 
Mixed venous oxygen saturation –0.249 <0.0001 0.312 <0.0001 
Echocardiographic parameters     
TAPSE –0.315 <0.0001 0.300 <0.0001 
RV myocardial performance 
index (Tei index) 
–0.011 0.901 0.062 0.092 
RV S’ –0.176 0.012 0.126 0.073 
TAPSE/Systolic PAP ratio –0.168 0.016 0.258 <0.0001 
RA area 0.342 <0.0001 –0.333 <0.0001 
LA diameter 0.310 <0.0001 0.310 <0.0001 
Renal function     
Renal filtration gradient –0.279 <0.0001 0.283 <0.0001 
Urine PCR 0.180 0.0099 –0.240 0.0005 
Urine ACR 0.179 0.0104 –0.238 0.0006 
Urine α1MCR 0.397 <0.0001 –0.523 <0.0001 
Renal Doppler 
Ultrasonography 
    
RRI 0.237 <0.0001 –0.430 <0.0001 
RVSI 0.486 <0.0001 –0.433 <0.0001 
Neurohormonal status     
BNP 0.343 <0.0001 –0.416 <0.0001 
Copeptin 0.554 <0.0001 –0.599 <0.0001 
Urine FeNa 0.447 <0.0001 –0.492 <0.0001 
Hydration status     
ECW/ICW ratio 0.085 0.246 –0.261 0.0003 
Intra-abdominal pressure 
measurement 
    
Intra-abdominal pressure 0.333 <0.0001 –0.327 <0.0001 
Pearson or Spearman correlation was considered as appropriate. *All available study variables were included in 
the analysis, but only variables that were significant in the analysis are presented here; in addition, paO2 and 
paCO2 are presented based on their clinical role. †After application of the Bonferroni correction, p<0.0006 was 
considered significant. ‡Blood gas measurements were taken from arterialized capillary ear lobe blood during 
right heart catheterization. In patients with long-term oxygen treatment, oxygen was applied via nasal cannula at 
the previously prescribed flow rate. 
 
6MWD=6-min walk distance; ACR=albumin-to-creatinine ratio; α1MCR=α1-microglobulin-to-creatinine ratio; 
BNP=b-type natriuretic peptide; CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; 
ECW=extracellular water; E/e’ ratio=ratio of mitral inflow velocity to lateral annular relaxation velocity; 
eGFR=estimated glomerular filtration rate; FeNa=fractional excretion of sodium; ICW=intracellular water; 
LA=left atrial; LVEF=left ventricular ejection fraction; MAP=mean arterial pressure; PaCO2=arterial carbon 
dioxide pressure; PaO2=arterial oxygen pressure; PAP=pulmonary arterial pressure; PCR=protein-to-creatinine 
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 ratio; PCWP=pulmonary capillary wedge pressure; RA=right atrial; RAP=right atrial pressure; RV=right 
ventricular; RV S’=systolic annular tissue velocity of the lateral tricuspid annulus; RVSI=renal venous stasis 
index; TAPSE=tricuspid annular plane systolic excursion. 
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 Table S7. Clinical characteristics, invasive hemodynamics, echocardiographic data, renal function, and neurohormonal and hydration status according to PH groups 
 No PH 
 
 
 
(n=40) 
Group 1 PH 
(pulmonary arterial 
hypertension) 
 
(n=46) 
Group 2 PH 
(PH due to left 
heart disease) 
 
(n=30) 
Group 3 PH 
(PH due to lung 
disease and/or 
hypoxemia) 
(n=41) 
Group 4 PH 
(chronic 
thromboembolic 
PH) 
(n=34) 
Group 5 PH 
(PH with unclear 
multifactorial 
mechanisms) 
(n=14) 
p value* 
 
Baseline clinical data        
Oxygen supply, n (%)   27 (58.7) 13 (43.3) 35 (85.4) 17 (50.0) 14 (100) <0.0001 
6MWD, m 313.15±126.56 309.07±153.40 269.60±115.46 199.12±105.30 308.38±147.46 239.43±104.40 <0.0001 
NYHA classification, n (%)        0.0054 
   1–2 10 (25) 17 (37.0) 5 (16.7) 3 (7.3) 8 (23.5) 1 (7.1)  
   3–4 30 (75) 29 (63.0) 25 (83.3) 38 (92.7) 26 (76.5) 13 (92.9)  
Comorbidities, n (%)        
Hypertension 23 (57.5) 21 (45.7) 27 (90.0) 32 (78.0) 18 (52.9) 7 (50.0) <0.0001 
Diabetes mellitus 8 (20.0) 8 (17.4) 11 (36.7) 11 (26.8) 6 (17.6) 4 (28.6) 0.388 
Atrial fibrillation 10 (25.0) 7 (15.2) 24 (80.0) 6 (14.6) 7 (20.6) 2 (14.3) <0.0001 
Maintenance therapy        
ACEi or ARB, n (%) 18 (45.0) 12 (26.1) 21 (70.0) 18 (43.9) 9 (26.5) 5 (35.7) 0.0027 
Loop diuretic dose, mg/day 0.0 [0.0–35.0] 40.0 [0.0–65.0] 50.0 [20.0–90.0] 40.0 [0.0–50.0] 40.0 [0.0–80.0] 40.0 [0.0–80.0] 0.0017 
Thiazide diuretic, n (%)  9 (22.5) 18 (39.1) 11 (36.7) 17 (41.5) 12 (35.3) 5 (35.7) 0.567 
Aldosterone antagonist, n (%) 8 (20.0) 22 (47.8) 12 (40.0) 13 (31.7) 17 (50.0) 4 (28.6) 0.0562 
Triamterene, n (%) 0 (0) 3 (6.5) 0 (0) 0 (0) 1 (2.9) 1 (7.1) 0.197 
PH-specific therapy, n (%)       <0.0001 
Treatment-naive 40 (100) 10 (21.7) 21 (70.0) 22 (53.7) 18 (52.9) 5 (35.7)  
Monotherapy 0 (0) 14 (30.4) 9 (30) 11 (26.8)  10 (29.4) 5 (35.7)  
Dual therapy 0 (0) 14 (30.4) 0 (0) 6 (14.6) 4 (11.7) 4 (28.6)  
>Triple therapy 0 (0) 8 (17.4) 0 (0) 2 (4.9) 2 (5.9) 0 (0)  
Hemodynamics        
Mean PAP, mm Hg 17.68±4.60 42.13±18.07 37.90±12.03 35.63±9.31 36.91±8.25 46.00±11.75 <0.0001 
PVR, dyn.s/cm5 151.5 [89.5–223.8] 547.5 [343.8–786.5] 315.5 [166.3–478.5] 486.0 [344.5–707.5] 454.5 [334.0–632.5] 519.5 [475.0–613.5] <0.0001 
RAP, mm Hg 2.75±4.74 5.24±5.61 9.97±6.08 5.29±5.55 5.53±5.05 8.93±5.44 <0.0001 
Cardiac index, L/min/m2 3.10±1.41 2.69±0.80 2.68±0.92 2.47±0.67 2.56±0.64 2.99±1.31 0.0533 
PCWP, mm Hg 7.0 [4.0–10.0] 8.5 [5.0–11.3] 19.0 [12.8–24.3] 7.0 [4.5–10.0] 8.0 [5.0–11.3] 12.0 [8.5–15.3] <0.0001 
Mixed venous oxygen 
saturation, % 
67.65±7.01  64.69±8.81  61.91±8.81 62.69±7.05 60.73±8.72 64.05±8.51 0.0083 
Heart rate, beats/min 71.45±11.11 70.39±11.46 66.13±12.01 73.98±12.91 72.15±13.56 97.71±21.30 0.0306 
MAP, mm Hg† 86.28±10.54 81.28±10.42 82.94±10.16 84.91±13.16 82.58±13.07 84.52±10.88 0.191 
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 Echocardiographic 
parameters 
       
Right heart        
TAPSE, mm 21.45±4.83 20.22±4.25 18.07±4.09 19.07±4.02 19.82±3.55 20.86±2.77 0.0269 
RV myocardial performance 
index (Tei index) 
0.40±0.19 0.52±0.22 0.43±0.19 0.54±0.22 0.52±0.25 0.49±0.27 0.237 
RV S’, cm/s 12.40±3.88 11.76 ±3.71 10.62±3.37 10.71±3.13 11.91±3.27 12.79±3.30 0.112 
TAPSE/Systolic PAP ratio 0.67±0.24 0.31±0.15 0.32±0.11 0.33±0.16 0.35±0.15 0.32±0.10 <0.0001 
Tricuspid insufficiency       0.159 
   Mild 23 (57.5) 14 (30.4) 6 (20.0) 14 (34.1) 8 (23.5) 3 (21.4)  
   Moderate 12 (30.0) 22 (47.8) 14 (46.7) 15 (36.6) 16 (47.1) 4 (28.6)  
   Severe  5 (12.5) 10 (21.7) 10 (33.3) 12 (29.2) 10 (29.4) 7 (50)  
RA area, m2 15.15±6.47 18.42±6.56 20.70±6.93 19.25±6.62 20.78±6.00 21.85±5.58 0.0009 
RV diameter, mm 36.43±7.88 42.13±8.29 40.31±8.02 42.20±8.24 41.21±6.16 44.57±7.86 0.0031 
IVC, cm 2.15±0.47 2.25±0.59 2.37±0.41 2.30±0.46 2.27±0.43 2.45±0.50 0.317 
Left heart        
LVEF, % 60.0 [58.1–65.0] 60.5 [60.0–65.0] 60.0 [55.0–65.0] 60.0 [60.0–65.0] 60.0 [60.0–65.0] 60.0 [60.0–65.0] 0.161 
LA diameter, mm 40.87±7.60 40.70±6.90 47.47±6.40 40.89±6.08 40.44±5.40 43.69±5.22 <0.0001 
LVEDD, mm 47.78±5.09 44.40±5.96 49.20±4.81 44.39±5.48 45.79±5.60 44.00±3.49 <0.0001 
E/e’ ratio 11.69±4.64 11.03±2.83 20.44±6.03 13.30±4.91 11.57±4.48 11.68±3.61 <0.0001 
Renal function        
Serum creatinine, mg/dL‡  0.91±0.45 1.04±0.43 1.23±0.50 0.99±0.43 0.99±0.42 0.78±0.25 0.0175 
Cystatin C, mg/L 0.97 [0.76–1.21] 1.19 [0.93–1.50] 1.36 [1.10–1.98] 1.09 [0.94–1.73] 1.07 [0.88–1.52] 1.06 [0.98–1.22] 0.0032 
Urea, mg/dL§ 39.98±29.56 45.67±42.10 61.57±34.11 49.05±29.86 49.15±44.64 35.50±14.40 0.143 
eGFR (CKD-EPI creatinine 
equation), mL/min/1.73 m2|| 
83.28±23.76 73.30±27.87 56.57±21.63 77.15±25.32 71.97±25.05 89.50±21.14 <0.0001 
eGFR (CKD-EPI creatinine-
cystatin C equation), 
mL/min/1.73 m2# 
80.60±27.39 67.46±27.24 50.77±20.19 69.30±26.56 66.91±26.29 78.07±19.50 <0.0001 
Renal filtration gradient, mm 
Hg** 
73.88±10.66 66.19±10.32 65.01±11.71 70.03±14.57 68.05±13.88 68.45±11.52 0.0288 
Urine PCR, mg/g creatinine 54.3 [44.9–82.9] 57.0 [35.9–106.3] 57.7 [35.6–131.7] 70.5 [46.7–146.2] 50.2 [36.4–121.9] 64.1 [44.8–111.9] 0.443 
Urine ACR, mg/g creatinine  11.6 [6.1–17.0] 9.2 [5.3–27.1] 12.1 [7.9–39.7] 11.5 [6.6–66.2] 11.7 [7.5–29.3] 16.0 [6.5–55.3] 0.442 
Urine α1MCR, mg/g 
creatinine 
9.8 [15.9–18.6] 8.7 [4.9–17.6] 15.3 [9.3–27.9] 13.1 [5.6–34.5] 11.2 [4.7–22.0] 7.6 [6.2–11.5] 0.071 
Acanthocyturia, n (%) 1 (2.5) 5 (10.9) 0 (0) 1 (2.4) 0 (0) 0 (0) 0.057 
Sterile leukocyturia, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.9) 1 (7.1) 0.135 
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 Intrarenal Doppler 
Ultrasonography 
       
Congestion stage       <0.0001 
   0 27 (67.5)  10 (21.7) 1 (3.3) 1 (24.4) 9 (26.5) 2 (14.3)  
   1 13 (32.5) 20 (43.5) 12 (40) 16 (39.0) 14 (41.2) 6 (42.9)  
   2 0 (0)  11 (23.9) 7 (23.3) 10 (24.4) 9 (26.5) 4 (28.6)  
   3 0 (0) 5 (10.9) 10 (33.3) 5 (12.2) 2 (5.9) 2 (14.3)  
Venous impedance index of 
1.0 
13 (32.5) 36 (78.3) 29 (96.7) 31 (75.6) 25 (73.5) 12 (85.7) 0.482 
RVSI 0.0 [0.00–0.09] 0.13 [0.04–0.34] 0.27 [0.11–0.46] 0.09 [0.02–0.29] 0.12 [0.00–0.29] 0.15 [0.06–0.36] <0.0001 
RRI 0.67±0.05 0.71±0.07 0.76±0.06 0.71±0.08 0.73±0.07 0.71±0.07 <0.0001 
Neurohormonal status        
BNP, pg/mL 51.00 [22.5–175.5] 134.00 [375.5–324.8] 232.50 [157.5–590.0] 114.00 [55.0–538.5] 160.00 [98.5–314.5] 196.00 [45.8–531.0] <0.0001 
Copeptin, pmol/L 6.95 [4.2–13.5] 7.95 [5.2–18.9] 15.45 [6.4–39.2] 14.15 [8.0–27.7] 16.30 [6.8–23.1] 11.35 [6.1–20.1] 0.0063 
Urine FeNa, % 0.60 [0.4–1.1] 0.65 [0.3–1.4] 1.20 [0.6–1.9] 0.80 [0.4–1.3] 0.50 [0.3–1.4] 0.4 [0.3–0.5] 0.0162 
Sodium, mmol/L 139.33±3.24 139.24±3.14 139.90±2.90 139.66±3.03 139.47±3.52 140.50±1.51 0.783 
BUN-to-creatinine ratio 20.28±8.18 19.09±6.80 23.05±7.86 22.58±7.22 21.47±7.84 21.29±6.46 0.189 
Aldosterone, ng/dL 4.70 [3.00–8.45] 8.85 [3.90–19.88] 5.75 [3.00–10.90] 4.70 [3.00–12.30] 6.30 [3.00–11.83] 4.65 [3.00–6.95] 0.079 
Potassium, mmol/L 3.75±0.45 3.61±0.39 3.78±0.45 3.60±0.43 3.62±0.40 3.67±0.25 0.271 
Urine Na/K ratio 3.52±2.31 2.80±1.70 3.61±2.65 3.45±2.54 3.04±2.16 2.90±1.94 0.53 
Hydration status        
Ascites, n (%) 0 (0) 2 (4.3) 3 (10.0) 1 (2.4) 1 (2.9) 0 (0) 0.588 
Peripheral edema, n (%) 9 (22.5) 14 (30.4) 9 (30.0) 12 (29.3) 11 (32.4) 5 (35.7) 0.929 
Pleural effusion, n (%) 0 (0) 5 (10.9) 3 (10.0) 3 (7.3) 2 (5.9) 4 (28.6) 0.0346 
Hydration status (as measured 
by bioimpedance), L 
0.11±1.64 0.97±2.02 1.05±2.53 0.54±2.21 0.71±2.28 1.35±1.91 0.282 
Total body water, L  38.46±7.26 36.13±7.81 37.73±6.31 38.85±8.35 37.76±7.91 38.16±5.58 0.679 
ECW, L 17.57±3.30 16.88±3.28 17.74±2.84 17.82±3.75 17.54±3.45 18.39±2.68 0.710 
ICW, L 20.88±4.31 19.51±4.53 19.97±4.01 20.03±5.12 20.22±4.93 19.76±3.37 0.669 
ECW/ICW ratio 0.85±0.09 0.87±0.12 0.90±0.12 0.86±0.13 0.88±0.13 0.94±0.11 0.132 
Intra-abdominal pressure 
measurement 
       
Intra-abdominal pressure, mm 
Hg 
6.0 [5.0–7.0] 7.0 [6.0–9.0] 8.5 [7.0–10.0] 7.0 [6.0–9.0] 7.0 [6.0–8.3] 8.0 [6.8–10.3] <0.0001 
Abdominal perfusion 
pressure, mm Hg††_ 
80.08±10.50 73.73±10.11 75.99±10.66 79.47±13.70 75.31±13.35 74.74±10.95 0.092 
Values are mean±SD, median [interquartile range], or n (%). 
D
ow
nloaded from
 http://ahajournals.org by on October 29, 2019
 *After application of the Bonferroni correction, p<0.0008 was considered significant. †MAP was calculated as (systolic blood pressure+2x diastolic pressure)/3. ‡To convert the 
values for serum creatinine to μmol/L, multiply by 88.4. §To convert the values for urea to BUN, multiply by 0.467. ||eGFR was calculated with the CKD-EPI equation based on 
serum creatinine.23 #eGFR was calculated with the CKD-EPI equation based on serum creatinine and cystatin C.22 **The renal filtration gradient was calculated as: MAP–2x 
intra-abdominal pressure.24 ††The abdominal perfusion pressure was calculated using the equation: MAP–intra-abdominal pressure.24 
6MWD=6-min walk distance; ACEi=angiotensin-converting enzyme inhibitor; ACR=albumin-to-creatinine ratio; α1MCR=α1-microglobulin-to-creatinine ratio; 
ARB=angiotensin receptor blocker; BNP=b-type natriuretic peptide; BUN=blood urea nitrogen; CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; 
ECW=extracellular water; E/e’ ratio=ratio of mitral inflow velocity to lateral annular relaxation velocity; eGFR=estimated glomerular filtration rate; FeNa=fractional excretion of 
sodium; ICW=intracellular water; IVC=inferior vena cava; LA=left atrial; LVEDD=left ventricular end-diastolic diameter; LVEF=left ventricular ejection fraction; MAP=mean 
arterial pressure; Na/K=sodium/potassium; NYHA=New York Heart Association; PAP=pulmonary arterial pressure; PCR=protein-to-creatinine ratio; PCWP=pulmonary 
capillary wedge pressure; PH=pulmonary hypertension; PVR=pulmonary vascular resistance; RA=right atrial; RAP=right atrial pressure; RRI=renal resistive index; RV=right 
ventricular; RV S’=systolic annular tissue velocity of the lateral tricuspid annulus; RVSI=renal venous stasis index; TAPSE=tricuspid annular plane systolic excursion.
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 Table S8. Outcomes in the RHC cohort. 
 
Outcome, n (%) RHC cohort (n=205) 
PH-related morbidity and death from any cause 91 (44.4%) 
Unscheduled hospitalizations for fluid overload 64 (31.2%) 
Escalations of PH-specific therapy 71 (34.6%) 
Death from any cause 21 (10.2%) 
Five patients underwent pulmonary thrombendarterectomy, and one patient underwent lung transplantation. 
RHC=right heart catheterization; PH=pulmonary hypertension.  
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 Table S9. Predictors of morbidity and mortality by the univariate Cox proportional hazard model. 
 Univariate 
Predictor HR (95% CI) p value 
Baseline clinical data   
Age 1.02 (1.00–1.03) 0.0439 
Sex 0.63 (0.42–0.95) 0.0265 
6MWD 0.997 (0.996–0.999) 0.0006 
NYHA classification 1.62 (1.19–2.20) 0.0024 
Pulmonary hypertension group 0.81 (0.72–0.91) <0.0001 
Diabetes mellitus 1.88 (1.21–2.91) 0.0048 
Atrial fibrillation 2.56 (1.68–3.88) <0.0001 
Uric acid 1.25 (1.16–1.34) <0.0001 
Hemodynamics   
Mean PAP 1.03 (1.02–1.04) <0.0001 
PVR 1.00 (1.00–1.00) <0.0001 
RAP 1.12 (1.07–1.14) <0.0001 
Cardiac index 0.54 (0.39–0.74) <0.0001 
PCWP 1.06 (1.03–1.09) <0.0001 
Mixed venous oxygen saturation 0.93 (0.91–0.96) <0.0001 
Echocardiographic parameters   
TAPSE 0.90 (0.86–0.94) <0.0001 
RV S’ 0.86 (0.80–0.93) <0.0001 
TAPSE/Systolic PAP ratio 0.05 (0.01–0.19) <0.0001 
Tricuspid insufficiency 1.76 (1.32–2.35) <0.0001 
RA area 1.07 (1.04–1.09) <0.0001 
RV diameter 1.05 (1.02–1.07) <0.0001 
IVC diameter 2.08 (1.38–3.13) <0.0001 
LVEF 0.98 (0.95–1.00) 0.0477 
LA diameter 1.07 (1.04–1.10) <0.0001 
E/e’ ratio 1.07 (1.03–1.11) <0.0001 
Renal function   
Serum creatinine 2.59 (1.83–3.66) <0.0001 
Cystatin C 2.18 (1.69–2.82) <0.0001 
Urea 1.01 (1.01–1.02) <0.0001 
eGFR (MDRD equation)* 0.99 (0.98–0.99) <0.0001 
eGFR (CKD-EPI creatinine equation) † 0.98 (0.97–0.98) <0.0001 
eGFR (CKD-EPI creatinine-cystatin C equation)‡ 0.98 (0.97–0.99) <0.0001 
Renal filtration gradient 0.97 (0.95–0.99) 0.0007 
Urine α1MCR 1.01 (1.01–1.02) <0.0001 
Urine FeNa 1.21 (1.09–1.34) <0.0001 
Renal Doppler ultrasonography   
RVSI tertiles 20.57 (9.03–46.87) <0.0001 
1st tertile RVSI group vs RVSI=0 2.31 (1.06–5.05) 0.0363 
2nd tertile RVSI group vs RVSI=0 3.63 (1.71–7.65) 0.0007 
3rd tertile RVSI group vs RVSI=0 8.70 (4.33–17.48) <0.0001 
Congestion stages 2.00 (1.63–2.44) <0.0001 
Stage 1 congestion vs stage 0 2.65 (1.29–5.44) 0.0078 
Stage 2 congestion vs stage 0 6.35 (3.08–13.09) <0.0001 
Stage 3 congestion vs stage 0 8.45 (3.98–17.96) <0.0001 
Venous impedance index  14.61 (4.31–49.55) <0.0001 
Neurohormonal status   
BNP 1.00 (1.00–1.00) <0.0001 
Copeptin 1.02 (1.02–1.03) <0.0001 
Aldosterone 1.01 (1.00–1.02) 0.0184 
Hydration status   
Hydration status (as measured by bioimpedance) 1.14 (1.03–1.25) 0.0081 
Extracellular/intracellular water 8.42 (1.31–54.25) 0.0251 
Ascites 2.85 (1.30–6.23) 0.0089 
Pleural effusion 2.27 (1.26–4.10) 0.0064 
Intra-abdominal pressure measurement   
Intra-abdominal pressure 1.25 (1.17–1.34) <0.0001 
Abdominal perfusion pressure§ 0.98 (0.96–1.00) 0.0226 
All available study variables were included in the univariate analysis, but only variables that were significant in 
the univariate analysis are presented here. *eGFR was calculated with the MDRD equation based on serum 
creatinine.25 †eGFR was calculated with the CKD-EPI equation based on serum creatinine.23 ‡eGFR was 
calculated with the CKD-EPI equation based on serum creatinine and cystatin C.22 §The abdominal perfusion 
pressure was calculated using the equation: MAP–intra-abdominal pressure, while MAP was calculated as 
(systolic blood pressure+2x diastolic pressure)/3.24 
6MWD=6-min walk distance; α1MCR=α1-microglobulin-to-creatinine ratio; BNP=b-type natriuretic peptide; 
CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; CI=confidence interval; E/e’ ratio=ratio of 
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 mitral inflow velocity to lateral annular relaxation velocity; eGFR=estimated glomerular filtration rate; 
FeNa=fractional excretion of sodium; HR=hazard ratio; IVC=inferior vena cava; LA=left atrial; LVEF=left 
ventricular ejection fraction; MAP=mean arterial pressure; MDRD=Modification of Diet in Renal Disease; 
NYHA=New York Heart Association; PAP=pulmonary arterial pressure; PCWP=pulmonary capillary wedge 
pressure; PVR=pulmonary vascular resistance; RA=right atrial; RAP=right atrial pressure; RV=right ventricular; 
RV S’=systolic annular tissue velocity of the lateral tricuspid annulus; RVSI=renal venous stasis index; 
TAPSE=tricuspid annular plane systolic excursion. 
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 Table S10. Predictors of unscheduled hospitalization due to fluid overload by the univariate Cox 
proportional hazard model.  
 Univariate 
Predictor HR (95% CI) p value 
Baseline clinical data   
Age 1.04 (1.01–1.06) 0.0013 
Sex 0.48 (0.29–0.79) 0.0039 
6MWD 0.996 (0.994–0.998) <0.0001 
NYHA classification 1.81 (1.24–2.64) 0.0022 
Pulmonary hypertension group 0.83 (0.72–0.95) 0.0083 
Diabetes mellitus 2.58 (1.56–4.27) <0.0001 
Atrial fibrillation 4.05 (2.47–6.63) <0.0001 
Sodium 0.93 (0.86–0.99) 0.0286 
Uric acid 1.29 (1.19–1.41) <0.0001 
Hemodynamics   
Mean PAP 1.02 (1.01–1.04) 0.0008 
PVR 1.00 (1.00–1.00) 0.0246 
RAP 1.15 (1.11–1.20) <0.0001 
Cardiac index 0.46 (0.31–0.68) <0.0001 
PCWP 1.08 (1.05–1.11) <0.0001 
Mixed venous oxygen saturation 0.92 (0.90–0.95) <0.0001 
Echocardiographic parameters   
TAPSE 0.86 (0.81–0.91) <0.0001 
RV S’ 0.77 (0.70–0.85) <0.0001 
TAPSE/Systolic PAP ratio 0.02 (0.00–0.18) <0.0001 
Tricuspid insufficiency 2.22 (1.55–3.18) <0.0001 
RA area 1.11 (1.07–1.14) <0.0001 
RV diameter 1.06 (1.03–1.10) <0.0001 
IVC diameter 2.60 (1.59–4.16) <0.0001 
LVEF 0.96 (0.94–0.99) 0.0037 
LA diameter 1.07 (1.04–1.11) <0.0001 
E/e’ ratio 1.08 (1.03–1.12) <0.0001 
Renal function   
Serum creatinine 3.40 (2.33–4.94) <0.0001 
Cystatin C 2.62 (1.99–3.45) <0.0001 
Urea 1.01 (1.01–1.02) <0.0001 
eGFR (MDRD equation)* 0.98 (0.97–0.99) <0.0001 
eGFR (CKD-EPI creatinine equation) † 0.97 (0.96–0.98) <0.0001 
eGFR (CKD-EPI creatinine-cystatin C equation)‡ 0.97 (0.96–0.98) <0.0001 
BUN-to-creatinine ratio 1.04 (1.01–1.07) 0.0117 
Renal filtration gradient 0.96 (0.94–0.98) <0.0001 
Urine α1MCR 1.01 (1.01–1.02) <0.0001 
Urine FeNa 1.21 (1.07–1.36) 0.0017 
Renal Doppler ultrasonography   
RVSI tertiles 1.71 (1.48–1.98) <0.0001 
1st tertile RVSI group vs RVSI=0 6.49 (1.42–29.64) 0.0157 
2nd tertile RVSI group vs RVSI=0 10.98 (2.52–47.76) 0.0014 
3rd tertile RVSI group vs RVSI=0 35.60 (8.54–148.38) <0.0001 
Congestion stages 2.49 (1.94–3.20) <0.0001 
Stage 1 congestion vs stage 0 7.36 (1.71–31.72) 0.0074 
Stage 2 congestion vs stage 0 25.51 (6.05–107.67) <0.0001 
Stage 3 congestion vs stage 0 32.17 (7.44–139.09) <0.0001 
Venous impedance index  121.10 (9.45–1552.61) <0.0001 
Neurohormonal status   
BNP 1.00 (1.00–1.00) <0.0001 
Copeptin 1.03 (1.02–1.04) <0.0001 
Aldosterone 1.02 (1.00–1.03) 0.0122 
Hydration status   
Hydration status (as measured by bioimpedance) 1.16 (1.04–1.29) 0.0089 
Extracellular/intracellular water 14.97 (1.66–135.09) 0.0159 
Extracellular water 1.09 (1.01–1.18) 0.0280 
Ascites 3.11 (1.24–7.77) 0.0153 
Pleural effusion 2.42 (1.19–4.90) 0.0142 
Peripheral edema 2.09 (1.28–3.44) 0.0034 
Intra-abdominal pressure measurement   
Intra-abdominal pressure 1.36 (1.26–1.47) <0.0001 
Abdominal perfusion pressure§ 0.97 (0.95–1.00) 0.0210 
All available study variables were included in the univariate analysis, but only variables that were significant in 
the univariate analysis are presented here. *eGFR was calculated with the MDRD equation based on serum 
creatinine.25 †eGFR was calculated with the CKD-EPI equation based on serum creatinine.23 ‡eGFR was 
calculated with the CKD-EPI equation based on serum creatinine and cystatin C.22 §The abdominal perfusion 
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 pressure was calculated using the equation: MAP–intra-abdominal pressure, while MAP was calculated as 
(systolic blood pressure+2x diastolic pressure)/3.24 
6MWD=6-min walk distance; α1MCR=α1-microglobulin-to-creatinine ratio; BNP=b-type natriuretic peptide; 
BUN=blood urea nitrogen; CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; CI=confidence 
interval; E/e’ ratio=ratio of mitral inflow velocity to lateral annular relaxation velocity; eGFR=estimated 
glomerular filtration rate; FeNa=fractional excretion of sodium; IVC=inferior vena cava; HR=hazard ratio; 
LA=left atrial; LVEF=left ventricular ejection fraction; MAP=mean arterial pressure; MDRD=Modification of 
Diet in Renal Disease; NYHA=New York Heart Association; PAP=pulmonary arterial pressure; PCR=protein-
to-creatinine ratio; PCWP=pulmonary capillary wedge pressure; PVR=pulmonary vascular resistance; RA=right 
atrial; RAP = right atrial pressure; RV=right ventricular; RV S’=systolic annular tissue velocity of the lateral 
tricuspid annulus; RVSI=renal venous stasis index; TAPSE=tricuspid annular plane systolic excursion.  
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 Table S11. Predictors of escalation of PH-specific therapy by the univariate Cox proportional hazard 
model. 
 Univariate 
Predictor HR (95% CI) p value 
Baseline clinical data   
6MWD 0.997 (0.995–0.999) 0.0013 
NYHA classification  1.59 (1.11–2.27) 0.0110 
Pulmonary hypertension group 0.79 (0.69–0.91) 0.0008 
Diabetes mellitus 1.90 (1.16–3.12) 0.0105 
Atrial fibrillation 1.79 (1.11–2.89) 0.0177 
Potassium 0.49 (0.28–0.88) 0.0162 
Uric acid 1.26 (1.16–1.36) <0.0001 
Hemodynamics   
Mean PAP 1.03 (1.02–1.04) <0.0001 
PVR 1.00 (1.00–1.00) <0.0001 
RAP 1.08 (1.04–1.12) <0.0001 
Cardiac index 0.41 (0.28–0.60) <0.0001 
PCWP 1.04 (1.01–1.07) 0.0072 
Mixed venous oxygen saturation 0.92 (0.90–0.95) <0.0001 
Echocardiographic parameters   
TAPSE 0.89 (0.85–0.94) <0.0001 
RV S’ 0.84 (0.77–0.91) <0.0001 
TAPSE/Systolic PAP ratio 0.04 (0.01–0.21) <0.0001 
Tricuspid insufficiency 1.54 (1.12–2.12) 0.0079 
RA area 1.05 (1.02–1.09) 0.0013 
RV diameter 1.05 (1.02–1.08) 0.0005 
IVC diameter 2.00 (1.25–3.19) 0.0037 
LA diameter 1.05 (1.01–1.08) 0.0072 
LVEDD 0.95 (0.91–0.99) 0.0221 
E/e’ ratio 1.07 (1.03–1.12) 0.0006 
Renal function   
Serum creatinine 2.55 (1.74–3.73) <0.0001 
Urea 1.01 (1.00–1.01) <0.0001 
Cystatin C 1.95 (1.50–2.55) <0.0001 
eGFR (MDRD equation)* 0.99 (0.98–0.99) <0.0001 
eGFR (CKD-EPI creatinine equation) † 0.98 (0.97–0.99) <0.0001 
eGFR (CKD-EPI creatinine-cystatin C equation)‡ 0.98 (0.97–0.99) <0.0001 
Renal filtration gradient 0.96 (0.94–0.99) 0.0007 
Urine α1MCR 1.01 (1.01–1.02) <0.0001 
Urine FeNa 1.24 (1.10–1.39) <0.0001 
Renal Doppler ultrasonography   
RVSI tertiles 1.43 (1.26–1.63) <0.0001 
1st tertile RVSI group vs RVSI=0 2.16 (0.89–5.24) 0.0872 
2nd tertile RVSI group vs RVSI=0 3.52 (1.53–8.07) 0.0030 
3rd tertile RVSI group vs RVSI=0 7.03 (3.22–15.35) <0.0001 
Congestion stages 1.86 (1.49–2.33) <0.0001 
Stage 1 congestion vs stage 0 2.37 (1.05–5.35) 0.0373 
Stage 2 congestion vs stage 0 6.22 (2.79–13.87) <0.0001 
Stage 3 congestion vs stage 0 6.39 (2.73–14.97) <0.0001 
Venous impedance index  12.59 (3.20–49.45) <0.0001 
Neurohormonal status   
BNP 1.00 (1.00–1.00) <0.0001 
Copeptin 1.03 (1.02–1.04) <0.0001 
Hydration status   
Pleural effusion 2.15 (1.10–4.21) 0.0256 
Intra-abdominal pressure measurement   
Intra-abdominal pressure 1.22 (1.13–1.32) <0.0001 
Abdominal perfusion pressure§ 0.97 (0.95–0.99) 0.0098 
All available study variables were included in the univariate analysis, but only variables that were significant in 
the univariate analysis are presented here. *eGFR was calculated with the MDRD equation based on serum 
creatinine.25 †eGFR was calculated with the CKD-EPI equation based on serum creatinine.23 ‡eGFR was 
calculated with the CKD-EPI equation based on serum creatinine and cystatin C.22 §The abdominal perfusion 
pressure was calculated using the equation: MAP–intra-abdominal pressure, while MAP was calculated as 
(systolic blood pressure+2x diastolic pressure)/3.24 
6MWD=6-min walk distance; α1MCR=α1-microglobulin-to-creatinine ratio; BNP=b-type natriuretic peptide; 
CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; CI=confidence interval; E/e’ ratio=ratio of 
mitral inflow velocity to lateral annular relaxation velocity; eGFR=estimated glomerular filtration rate; 
FeNa=fractional excretion of sodium; HR=hazard ratio; IVC=inferior vena cava; LA=left atrial; LVEDD=left 
ventricular end-diastolic diameter; MAP=mean arterial pressure; MDRD=Modification of Diet in Renal Disease; 
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 NYHA=New York Heart Association; PAP=pulmonary arterial pressure; PCWP=pulmonary capillary wedge 
pressure; PH=pulmonary hypertension; PVR=pulmonary vascular resistance; RA=right atrial; RAP=right atrial 
pressure; RV=right ventricular; RV S’=systolic annular tissue velocity of the lateral tricuspid annulus; 
RVSI=renal venous stasis index; TAPSE=tricuspid annular plane systolic excursion.  
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 Table S12. Predictors of death from any cause by the univariate Cox proportional hazard model. 
 
 Univariate 
Predictor HR (95% CI) p value 
Baseline clinical data   
Sex 0.30 (0.12–0.77) 0.0127 
6MWD 1.0 (0.99–1.00) 0.0239 
NYHA classification 2.65 (1.30–5.41) 0.0074 
Uric acid 1.25 (1.09–1.43) 0.0018 
Hemodynamics   
RAP 1.08 (1.02–1.15) 0.0149 
Mixed venous oxygen saturation 0.92 (0.88–0.96) <0.0001 
Echocardiographic parameters   
TAPSE 0.88 (0.80–0.96) 0.0045 
RV S’ 0.74 (0.64–0.87) <0.0001 
TAPSE/Systolic PAP ratio 0.01 (0.00–0.17) 0.011 
RA area 1.10 (1.04–1.17) 0.0018 
RV diameter 1.07 (1.02–1.12) 0.0076 
Renal function   
Serum creatinine 2.14 (1.05–4.40) 0.0376 
Urea 1.01 (1.00–1.02) 0.0262 
Renal Doppler ultrasonography   
RVSI tertiles  0.065 
1st tertile RVSI group vs RVSI=0 2.00 (0.48–8.38) 0.342 
2nd tertile RVSI group vs RVSI=0 1.25 (0.25–6.17) 0.788 
3rd tertile RVSI group vs RVSI=0 4.33 (1.19–15.72) 0.026 
Congestion stages 1.39 (1.10–1.77) 0.0066 
Stage 1 congestion vs stage 0 1.29 (0.31–5.38) 0.732 
Stage 2 congestion vs stage 0 3.84 (1.02–14.48) 0.0469 
Stage 3 congestion vs stage 0 4.03 (0.96–16.86) 0.0564 
Neurohormonal status   
BNP 1.00 (1.00–1.00) 0.0012 
Copeptin 1.02 (1.00–1.04) 0.0193 
Intra-abdominal pressure measurement   
Intra-abdominal pressure 1.22 (1.06–1.41) 0.0069 
All available study variables were included in the univariate analysis, but only variables that were significant in 
the univariate analysis are presented here.  
6MWD=6-min walk distance; BNP=b-type natriuretic peptide; CI=confidence interval; HR=hazard ratio; 
NYHA=New York Heart Association; PAP=pulmonary arterial pressure; RA=right atrial; RAP=right atrial 
pressure; RV=right ventricular; RV S’=systolic annular tissue velocity of the lateral tricuspid annulus; 
RVSI=renal venous stasis index; TAPSE=tricuspid annular plane systolic excursion. 
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 Table S13. Performance of RVSI versus IRVF patterns in models including both variables for prediction 
of secondary endpoints. 
 Wald statistic 
Secondary endpoint Unplanned 
hospitalization due to 
fluid overload 
Escalation of PH-specific 
therapy 
All-cause mortality 
RVSI 6.163 0.721 0.611 
IRVF patterns 0.996 2.675 0.204 
Higher Wald statistic indicates superiority for prediction of endpoint. RVSI was superior to IRVF patterns in 
models including both RVSI and IRVF patterns as predictor variables for all component endpoints except need 
for escalation of PH-specific therapy. 
IRVF=intrarenal venous flow; PH=pulmonary hypertension; RVSI=renal venous stasis index. 
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Figure S1. IRVF patterns and associated clinical parameters. 
 
  
Severity of renal congestion can be evaluated by identifying four distinct IRVF patterns using renal Doppler 
ultrasonography. The figure illustrates the associations of these IRVF patterns with RAP and renal function (a), 
right ventricular systolic function and right atrial area (b), neurohormonal (c), and hydration status (d). Fluid 
overload as measured by bioimpedance is likely to occur as a result of hemodynamic alterations and 
neurohormonal activation leading to a deterioration of renal function and fluid retention. 
BNP=b-type natriuretic peptide; D=diastole; eGFR=estimated glomerular filtration rate (based on Chronic 
Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation22); IRVF=intrarenal venous flow; 
RA=right atrial; RAP=right atrial pressure; S=systole; TAPSE=tricuspid annular plane systolic excursion; 
VII=venous impedance index.  
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Figure S2. Correlation of RVSI with RAP (a), TAPSE (b), eGFR (c), and intra-abdominal pressure (d). 
 
 
 
eGFR=estimated glomerular filtration rate (based on Chronic Kidney Disease Epidemiology Collaboration 
creatinine-cystatin C equation22); RAP=right atrial pressure; RVSI=renal venous stasis index; TAPSE=tricuspid 
annular plane systolic excursion.  
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Figure S3. Kaplan-Meier estimate curves according to RVSI tertiles. 
 
 
 
Patients in the 3rd tertile RVSI group had a significantly higher probability than other patients of the following 
individual components of the composite endpoint: unscheduled hospitalization for fluid overload (p<0.0001) (a) 
and escalation of PH-specific therapy (p<0.0001) (b). After Bonferroni correction, death from any cause did not 
show a significant difference between patients in the 3rd tertile RVSI group and other patients (p=0.0412) (c). 
PH=pulmonary hypertension; RVSI = renal venous stasis index. 
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Figure S4. Kaplan-Meier estimate curves according to IRVF patterns.  
 
 
 
Patients in the highest IRVF pattern group had a significantly higher probability than other patients of the 
composite endpoint of PH-related morbidity or death from any cause (p<0.0001) (a) and the following 
individual components of the composite endpoint: unscheduled hospitalization for fluid overload (p<0.0001) (b) 
and escalation of PH-specific therapy (p<0.0001) (c). After Bonferroni correction, death from any cause did not 
show a significant difference between patients in the highest IRVF pattern group and other patients (p=0.0387) 
(d).  
IRVF=intrarenal venous flow; PH=pulmonary hypertension. 
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Figure S5. Comparison of RVSI and IRVF patterns as predictors of the primary and secondary clinical 
endpoints.  
 
 
 
Receiver operating characteristic analyses indicate that RVSI was superior to the four IRVF patterns as a 
predictor of the composite primary endpoint (AUC: 0.789 and 0.761, respectively; p=0.038) (a), and for the 
prediction of unplanned hospitalization due to fluid overload (AUC: 0.843 and 0.813, respectively; p=0.045) (b) 
but not escalation of pulmonary hypertension-specific therapy (AUC: 0.737 and 0.724, respectively; p=0.36) (c), 
nor all-cause mortality (AUC: 0.650 and 0.668, respectively; p=0.37) (d). Diagonal segments are produced by 
ties.  
AUC=area under the curve; IRVF=intrarenal venous flow; RVSI=renal venous stasis index. 
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